[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1311
1. Han HS, Chang CB, Seong SC, Lee S, Lee MC: Evaluation of anatomic references for tibial sagittal alignment in total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc; 2008 Apr;16(4):373-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of anatomic references for tibial sagittal alignment in total knee arthroplasty.
  • Angles between the mechanical axis (MA), the tibial anatomical axis (TAA), the anterior tibial cortex (ATC) and the fibular shaft axis (FSA) were measured, and then medial and lateral tibial slope angles were measured using all axes.
  • Mean angles between MA and the other anatomical reference lines (TAA, ATC and FSA) were 0.9, 2.2 and -2.1 degrees, respectively.
  • The mean values of lateral tibial slopes with respect to MA, TAA, ATC and FSA were 8.7, 10, 12 and 7.3, respectively, and their intra- and inter-observer reliabilities were higher than those of medial tibial slopes.

  • MedlinePlus Health Information. consumer health - Knee Replacement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Br. 2002 Aug;84(6):858-60 [12211678.001]
  • [Cites] Clin Orthop Relat Res. 2003 Nov;(416):177-84 [14646759.001]
  • [Cites] J Orthop Sci. 2005;10 (1):42-7 [15666122.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 1996;82(3):195-200 [9005456.001]
  • [Cites] Clin Orthop Relat Res. 1991 Aug;(269):63-9 [1864058.001]
  • [Cites] Clin Orthop Relat Res. 1996 Oct;(331):102-6 [8895625.001]
  • [Cites] J Arthroplasty. 2000 Feb;15(2):224-7 [10708090.001]
  • [Cites] J Arthroplasty. 1988;3 Suppl:S51-7 [3199140.001]
  • [Cites] J Orthop Res. 1989;7(1):132-7 [2908904.001]
  • [Cites] J Arthroplasty. 1987;2(4):317-26 [3430160.001]
  • [Cites] J Arthroplasty. 1998 Aug;13(5):552-8 [9726321.001]
  • [Cites] Am J Sports Med. 2005 Mar;33(3):378-87 [15716253.001]
  • [Cites] Acta Orthop Scand. 2004 Oct;75(5):573-9 [15513489.001]
  • [Cites] J Radiol. 1993 Jan;74(1):27-33 [8483148.001]
  • [Cites] J Bone Joint Surg Am. 2004 Mar;86-A(3):506-11 [14996875.001]
  • [Cites] J Bone Joint Surg Br. 2003 Aug;85(6):830-5 [12931800.001]
  • [Cites] Z Orthop Ihre Grenzgeb. 2003 Mar-Apr;141(2):143-7 [12695949.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):180-6 [15346071.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):424-33 [11953637.001]
  • [Cites] J Bone Joint Surg Am. 2000 Nov;82-A(11):1603-8 [11097451.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):194-8 [15346073.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 1993;79(8):625-34 [7938808.001]
  • [Cites] J Arthroplasty. 1996 Jan;11(1):99-103 [8676126.001]
  • [Cites] J Arthroplasty. 2005 Apr;20(3):282-8 [15809943.001]
  • [Cites] Knee Surg Sports Traumatol Arthrosc. 2001 Sep;9(5):296-8 [11685361.001]
  • [Cites] Knee Surg Sports Traumatol Arthrosc. 2005 Jan;13(1):38-43 [15045163.001]
  • [Cites] J Bone Joint Surg Br. 2004 Aug;86(6):818-23 [15330021.001]
  • [Cites] Knee Surg Sports Traumatol Arthrosc. 2005 Apr;13(3):193-6 [15824934.001]
  • [Cites] Am J Sports Med. 2004 Mar;32(2):376-82 [14977661.001]
  • [Cites] Am J Knee Surg. 1999 Summer;12(3):165-8 [10496466.001]
  • [Cites] J Arthroplasty. 2000 Oct;15(7):916-20 [11061453.001]
  • [Cites] Arthroscopy. 2004 Apr;20(4):366-72 [15067275.001]
  • [Cites] Biomed Tech (Berl). 2003 Dec;48(12 ):339-43 [14740521.001]
  • (PMID = 18270685.001).
  • [ISSN] 0942-2056
  • [Journal-full-title] Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA
  • [ISO-abbreviation] Knee Surg Sports Traumatol Arthrosc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


2. Mitsiades CS, Hayden P, Kotoula V, McMillin DW, McMullan C, Negri J, Delmore JE, Poulaki V, Mitsiades N: Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition. J Clin Endocrinol Metab; 2007 Dec;92(12):4845-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.
  • CONTEXT: The Bcl-2 family of proteins regulates apoptosis in various models and may represent a promising therapeutic target in human malignancies.
  • OBJECTIVE/METHODS: We evaluated the sensitivity of thyroid carcinoma cell lines (two papillary, one follicular, two anaplastic, three medullary) in vitro to BH3I-1 and BH3I-2', two cell-permeable inhibitors of the Bcl-2 homology (BH)-3 domain-mediated interaction between proapoptotic and antiapoptotic Bcl-2 family members.
  • The thyroid carcinoma cell line FRO was stably transfected with cDNA for Bcl-2 or constitutively active Akt and evaluated for sensitivity to BH3-domain inhibition.
  • RESULTS: BH3-domain inhibition disrupted the mitochondrial membrane potential in thyroid carcinoma cells, induced caspase-dependent apoptosis, and potently sensitized them to sublethal concentrations of doxorubicin and the proteasome inhibitor bortezomib (Velcade).
  • CONCLUSIONS: Bcl-2 expression protects thyroid carcinomas against chemotherapy-induced apoptosis.
  • Nevertheless, overexpression of Bcl-2 may result in "oncogene addiction" of the cancer cell, which can be exploited by using BH3-domain inhibitors alone or in combination with other agents, including conventional chemotherapeutics (such as doxorubicin) or novel targeted therapies (such as the proteasome inhibitor bortezomib), for the treatment of aggressive thyroid cancer, including the medullary and anaplastic types.
  • [MeSH-major] Carcinoma / genetics. Carcinoma, Medullary / genetics. Genes, bcl-2 / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848408.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / BH3 Interacting Domain Death Agonist Protein; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 0 / RNA, Neoplasm; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue; 69G8BD63PP / Bortezomib; 80168379AG / Doxorubicin; EC 2.7.11.1 / Oncogene Protein v-akt
  •  go-up   go-down


3. Bhatia A, Rao A, Ang KK, Garden AS, Morrison WH, Rosenthal DI, Evans DB, Clayman G, Sherman SI, Schwartz DL: Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head Neck; 2010 Jul;32(7):829-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy.
  • BACKGROUND: The aim of this study was to review institutional outcomes for anaplastic thyroid cancer treated with conformal 3-dimensional radiotherapy (3DRT) or intensity-modulated radiotherapy (IMRT).
  • Patients without distant metastases receiving >or=50 Gy had superior survival outcomes; 5 such patients had no evidence of disease at last follow-up.
  • CONCLUSIONS: Outcomes for anaplastic thyroid cancer treated with 3DRT or IMRT remain equivalent to historical results.
  • Healthy patients with localized disease who tolerate full dose irradiation can potentially enjoy prolonged survival.
  • [MeSH-major] Radiotherapy, Intensity-Modulated. Thyroid Neoplasms / mortality. Thyroid Neoplasms / radiotherapy


Advertisement
4. Cerilli LA, Frable WJ, Spafford MF: Anaplastic carcinoma of the thyroid with chondroblastoma features mimicking papillary carcinoma: a case report. Acta Cytol; 2007 Sep-Oct;51(5):825-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic carcinoma of the thyroid with chondroblastoma features mimicking papillary carcinoma: a case report.
  • BACKGROUND: An unusual case of anaplastic carcinoma of the thyroid arising from a metastatic focus of papillary carcinoma.
  • CASE: The tumor affected a 69-year-old woman with a history of total thyroidectomy for papillary thyroid carcinoma 4 years previously.
  • A small, embedded focus of residual follicular variant of papillary carcinoma was present.
  • The patient died of disease 3 months later.
  • CONCLUSION: This "chondroblastoma" variant of anaplastic thyroid carcinoma has not been reported to date.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Papillary / pathology. Chondroblastoma / pathology. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Chondroblastoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17910356.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


6. Goodman A, Mensch JM, Jay M, French KE, Mitchell MF, Fritz SL: Retention and attrition factors for female certified athletic trainers in the National Collegiate Athletic Association Division I Football Bowl Subdivision setting. J Athl Train; 2010 May-Jun;45(3):287-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retention and attrition factors for female certified athletic trainers in the National Collegiate Athletic Association Division I Football Bowl Subdivision setting.
  • However, little is known about the retention and attrition of female certified athletic trainers (ATs) in certain settings.
  • OBJECTIVE: To gain insight and understanding into the factors and circumstances affecting female ATs' decisions to persist in or leave the National Collegiate Athletic Association Division I Football Bowl Subdivision (NCAA D-I FBS) setting.
  • [MeSH-major] Athletic Injuries. Burnout, Professional. Football / injuries. Personnel Turnover / statistics & numerical data. Sports Medicine / manpower

  • MedlinePlus Health Information. consumer health - Sports Fitness.
  • MedlinePlus Health Information. consumer health - Sports Injuries.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nurs Health Sci. 2001 Sep;3(3):161-72 [11882192.001]
  • [Cites] Phys Ther. 2009 Sep;89(9):946-56 [19608632.001]
  • [Cites] J Allied Health. 1978 Fall;7(4):281-7 [10239353.001]
  • [Cites] Acad Manage J. 1981 Sep;24(3):543-65 [10252608.001]
  • [Cites] J Prof Nurs. 1991 Jul-Aug;7(4):221-7 [1894842.001]
  • [Cites] Physiother Can. 1993 Fall;45(4):239-44 [10130907.001]
  • [Cites] J Allied Health. 1996 Summer;25(3):219-32 [8884434.001]
  • [Cites] J Adv Nurs. 1997 Feb;25(2):245-56 [9043997.001]
  • [Cites] Int J Nurs Stud. 2006 Feb;43(2):237-63 [15878771.001]
  • [Cites] Int J Nurs Stud. 2007 Feb;44(2):297-314 [16631760.001]
  • [Cites] J Athl Train. 2008 May-Jun;43(3):275-83 [18523564.001]
  • [Cites] J Athl Train. 2008 Jul-Aug;43(4):373-8 [18668170.001]
  • [Cites] J Athl Train. 2008 Sep-Oct;43(5):505-12 [18833313.001]
  • [Cites] J Athl Train. 2008 Sep-Oct;43(5):513-22 [18833314.001]
  • [Cites] J Allied Health. 2002 Fall;31(3):131-9 [12227263.001]
  • (PMID = 20446843.001).
  • [ISSN] 1938-162X
  • [Journal-full-title] Journal of athletic training
  • [ISO-abbreviation] J Athl Train
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2865968
  •  go-up   go-down


7. Hirokawa M, Haba R, Kushida Y, Bando K, Kuma S, Kihara M, Miyauchi A: Benign nodular goiter with spindle cell component. Pathol Int; 2010 Aug;60(8):586-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemically, they were positive for thyroglobulin and thyroid transcription factor-1.
  • We thought that the spindle cells are derived from follicular cell and non-neoplastic, and it is important to recognize this lesion to distinguish from aggressive and lethal components seen in papillary carcinoma or anaplastic carcinoma.
  • [MeSH-major] Carcinoma, Papillary / pathology. Goiter, Nodular / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20618737.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


8. Chiu CY, Wu YC, Jenq SF, Jap TS: Mutations in low-density lipoprotein receptor gene as a cause of hypercholesterolemia in Taiwan. Metabolism; 2005 Aug;54(8):1082-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We identified 6 mutations in LDLR gene, including heterozygous missense mutations I420T (ATC-->ACC), C660W (TGC-->TGG), H562Y (CAC-->TAC), and A606T (GCC-->ACC), and a heterozygous and a homozygous mutation in codon P664L (CCG-->CTG) as well as a homozygous large deletion of exons 6 to 8.

  • Genetic Alliance. consumer health - Hypercholesterolemia.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16092059.001).
  • [ISSN] 0026-0495
  • [Journal-full-title] Metabolism: clinical and experimental
  • [ISO-abbreviation] Metab. Clin. Exp.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, LDL
  •  go-up   go-down


9. Salnikov AV, Heldin NE, Stuhr LB, Wiig H, Gerber H, Reed RK, Rubin K: Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma. Int J Cancer; 2006 Dec 15;119(12):2795-802
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma.
  • The stroma of carcinomas shares several characteristics with inflamed tissues including a distorted vasculature, active angiogenesis and macrophage infiltration.
  • We show here that bevacizumab [rhuMab vascular endothelial growth factor (VEGF), Avastin], a monoclonal antibody to VEGF, at a dose of 5 mg/kg modulated inflammation in KAT-4 xenograft human anaplastic thyroid carcinoma tissue.
  • Our data suggest that carcinoma cell-derived VEGF either directly or indirectly participates in maintaining an inflammatory microenvironment in experimental KAT-4 carcinoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Inflammation / prevention & control. Thyroid Neoplasms / prevention & control. Vascular Endothelial Growth Factor A / immunology. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 17019708.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD31; 0 / Chemokines; 0 / Cytokines; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


10. Abou Chakra CN, Pariente A, Pinet M, Nkeng L, Moore N, Moride Y: Case series in drug safety: a review to determine characteristics and quality. Drug Saf; 2010 Dec 01;33(12):1081-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adverse effects involved mainly the skin (18.5%) and the circulatory system (13.8%).
  • The main suspected drug classes (Anatomical Therapeutic Chemical classification) were nervous system drugs (23.1%) and antineoplastic and immunomodulating agents (20.0%).

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cutis. 2007 Sep;80(3):231-7 [17956013.001]
  • [Cites] Therapie. 2009 Jul-Aug;64(4):289-94 [19804709.001]
  • [Cites] Eye (Lond). 2007 Apr;21(4):547-9 [16456589.001]
  • [Cites] CMAJ. 2005 Mar 15;172(6):765-7 [15767610.001]
  • [Cites] J Rheumatol. 2008 Mar;35(3):537-8 [18203307.001]
  • [Cites] Drug Saf. 2006;29(8):687-96 [16872242.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2006 Nov;15(11):808-12 [16700082.001]
  • [Cites] Intern Med J. 2006 Mar;36(3):162-9 [16503951.001]
  • [Cites] J Ocul Pharmacol Ther. 2004 Apr;20(2):179-82 [15117574.001]
  • [Cites] J Mich Dent Assoc. 2005 Nov;87(11):44-9 [16372548.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2007 May;16(5):581-7 [17471601.001]
  • [Cites] Ann Intern Med. 2003 May 20;138(10):807-11 [12755552.001]
  • [Cites] Eur J Clin Pharmacol. 2001 Apr;57(1):89-91 [11372600.001]
  • [Cites] Drug Saf. 2007;30(5):367-73 [17472416.001]
  • [Cites] Cutan Ocul Toxicol. 2008;27(1):5-9 [18330828.001]
  • [Cites] Drug Saf. 2008;31(12):1115-23 [19026028.001]
  • [Cites] Therapie. 1997 Mar-Apr;52(2):123-7 [9231506.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2006 Jul-Aug;72(4):286-9 [16880575.001]
  • [Cites] J Am Acad Dermatol. 2007 Apr;56(4):624-8 [17240478.001]
  • [Cites] Ophthalmology. 2008 Dec;115(12):2282-5 [18930555.001]
  • [Cites] Pediatrics. 2005 Nov;116(5):e675-80 [16230465.001]
  • [Cites] Drug Saf. 2006;29(2):143-9 [16454541.001]
  • [Cites] Br J Clin Pharmacol. 2008 Nov;66(5):689-94 [18754840.001]
  • [Cites] Reumatismo. 2005 Jan-Mar;57(1):44-51 [15776146.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):e19-22 [16779736.001]
  • [Cites] Drugs Aging. 2004;21(7):479-84 [15132714.001]
  • [Cites] Rev Med Chil. 2006 Jul;134(7):875-82 [17130971.001]
  • [Cites] Ophthalmology. 2006 Feb;113(2):308-14 [16406545.001]
  • [Cites] Ann Dermatol Venereol. 2003 Nov;130(11):1051-5 [14724542.001]
  • (PMID = 21077699.001).
  • [ISSN] 1179-1942
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  •  go-up   go-down


11. Sipos JA, Mazzaferri EL: The therapeutic management of differentiated thyroid cancer. Expert Opin Pharmacother; 2008 Oct;9(15):2627-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The therapeutic management of differentiated thyroid cancer.
  • BACKGROUND: The management of thyroid cancer is difficult because the tumors comprise a wide range of biologic behaviors, from small papillary thyroid microcarcinomas that pose little or no threat to survival for the patient, to anaplastic thyroid cancers that are arguably the most lethal tumor.
  • Although it may be difficult initially to determine at which end of the prognostic spectrum a patient resides, one can ordinarily estimate a patient's risk for tumor recurrence and mortality based on a triad of features as simple as the patient's age at the time of diagnosis, the tumor stage at presentation, and its initial response to therapy.
  • This is largely because randomized controlled trials are lacking as a result of the low incidence and generally favorable prognosis of the disease.
  • The treatment of these tumors rests on a fine balance of providing care that reflects the anticipated course of the disease without overtreating the patient or providing reassurance that is unfounded.
  • OBJECTIVE: To outline the treatment strategy for patients with differentiated thyroid cancer based on the available literature and to guide clinicians through a management algorithm utilizing patient and tumor characteristics.
  • METHODS: This review is limited to the treatment of patients with differentiated thyroid cancer - papillary and follicular thyroid cancer - and the standard therapy required for the majority of patients.
  • RESULTS/CONCLUSION: The treatment of differentiated thyroid cancer requires a multidisciplinary approach, involving an experienced surgeon, radiologists and an endocrinologist.
  • There are many unanswered questions in the management algorithm and ongoing research is needed to further define the best treatment strategy for patients with differentiated thyroid cancer.
  • [MeSH-major] Thyroid Neoplasms / therapy
  • [MeSH-minor] Cell Differentiation. Combined Modality Therapy. Hormone Replacement Therapy. Humans. Lymph Node Excision. Postoperative Complications. Radiotherapy Dosage. Thyroid Hormones / administration & dosage. Thyroidectomy. Thyrotropin / antagonists & inhibitors

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803450.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Thyroid Hormones; 9002-71-5 / Thyrotropin
  • [Number-of-references] 102
  •  go-up   go-down


12. Pelosi G, Fumagalli C, Trubia M, Sonzogni A, Rekhtman N, Maisonneuve P, Galetta D, Spaggiari L, Veronesi G, Scarpa A, Malpeli G, Viale G: Dual role of RASSF1 as a tumor suppressor and an oncogene in neuroendocrine tumors of the lung. Anticancer Res; 2010 Oct;30(10):4269-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Twenty typical carcinoids (TC), 11 atypical carcinoids (ATC), 11 large cell neuroendocrine carcinomas (LCNEC) and 16 small cell lung carcinomas (SCLC) were analyzed for RASSF1 promoter methylation, mRNA and protein expression, and loss of 3p21.3 locus.
  • A correlation was found between 3p21.3 allelic loss and decrease of RASSF1 A/E mRNA (p=0.023) and protein (p=0.043) expression in ATC, suggesting that 3p21.3 allelic loss contributed to the loss of gene expression.
  • [MeSH-minor] Adenocarcinoma / genetics. Aged. Carcinoma, Small Cell / genetics. Carcinoma, Squamous Cell / genetics. DNA Methylation. Female. Genes, Tumor Suppressor. Humans. In Situ Hybridization, Fluorescence. Loss of Heterozygosity. Male. Middle Aged. Oncogenes. Promoter Regions, Genetic. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21036752.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


13. Stucchi CM, Vaccaro V, Magherini A, Di Gregorio C, Greco G, Livolsi VA, Papi G: Hurthle cell follicular carcinoma of the thyroid gland presenting with diffuse meningeal carcinomatosis and evolving to anaplastic carcinoma. J Clin Pathol; 2007 Jul;60(7):831-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hurthle cell follicular carcinoma of the thyroid gland presenting with diffuse meningeal carcinomatosis and evolving to anaplastic carcinoma.
  • [MeSH-major] Adenocarcinoma, Follicular / secondary. Meningeal Neoplasms / secondary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Carcinoma / pathology. Disease Progression. Fatal Outcome. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2004 Mar;57(3):225-32 [14990587.001]
  • [Cites] Surgery. 2005 Dec;138(6):1152-7; discussion 1157-8 [16360403.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1304-9 [9824112.001]
  • (PMID = 17596549.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1995787
  •  go-up   go-down


14. Murugan AK, Bojdani E, Xing M: Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun; 2010 Mar 12;393(3):555-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.
  • In the present study, we investigated IDH1 and IDH2 mutations in follicular thyroid cancer (FTC) and anaplastic thyroid cancer (ATC), with the latter, like glioblastoma, having a rapidly aggressive and lethal clinical course.
  • By direct genomic DNA sequencing, we analyzed exon 4 of the IDH1 and IDH2 genes that harbored the mutation hot spots codon 132 and 172 of the two genes in glioblastoma, respectively, in 12 thyroid cancer cell lines, 20 FTC, and 18 ATC tumor samples.
  • A novel homozygous G367A IDH1 mutation, resulting in a G123R amino acid change in codon 123, was identified in a case of ATC.
  • A previously described IDH1 V71I mutation was found in a case of FTC and a case of ATC and no mutations were found in the cell lines.
  • The overall prevalence of mutations was thus 1/20 (5%) in FTC and 2/18 (11%) in ATC.
  • We did not find mutation in the IDH2 gene in these thyroid cancer cell lines and tumor samples.
  • Thus, functionally relevant IDH1 mutations can also occur in thyroid cancer, particularly ATC, suggesting a potential tumorigenic role of the IDH1 system that could represent a new therapeutic target for thyroid cancer.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33946-57 [15173171.001]
  • [Cites] N Engl J Med. 2009 Sep 10;361(11):1058-66 [19657110.001]
  • [Cites] Biochemistry. 1997 Nov 4;36(44):13743-7 [9354646.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30527-33 [10521434.001]
  • [Cites] Int J Oncol. 2008 Jan;32(1):101-11 [18097548.001]
  • [Cites] Endocrinol Metab Clin North Am. 2008 Jun;37(2):525-38, xi [18502341.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):597-602 [18985363.001]
  • [Cites] Hum Mutat. 2009 Jan;30(1):7-11 [19117336.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):765-73 [19228619.001]
  • [Cites] Science. 2009 Apr 10;324(5924):261-5 [19359588.001]
  • [Cites] Int J Cancer. 2009 Jul 15;125(2):353-5 [19378339.001]
  • [Cites] Cell Cycle. 2009 Jul 1;8(13):2122-4 [19411838.001]
  • [Cites] Neuro Oncol. 2009 Aug;11(4):341-7 [19435942.001]
  • [Cites] Arch Microbiol. 1997 Nov;168(5):412-20 [9325430.001]
  • (PMID = 20171178.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA134225-01A2; United States / NCI NIH HHS / CA / R01 CA113507; United States / NCI NIH HHS / CA / CA134225-01A2; United States / NCI NIH HHS / CA / R01CA134225-01; United States / NCI NIH HHS / CA / R01 CA134225
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human
  • [Other-IDs] NLM/ NIHMS182112; NLM/ PMC2838977
  •  go-up   go-down


15. Cox S, Southby J: Apricitabine--a novel nucleoside reverse transcriptase inhibitor for the treatment of HIV infection that is refractory to existing drugs. Expert Opin Investig Drugs; 2009 Feb;18(2):199-209
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Apricitabine (ATC) is a nucleoside reverse transcriptase inhibitor (NRTI) being developed for the treatment of HIV.
  • ATC has promising antiviral activity, including against HIV-1 containing reverse transcriptase mutations that confer resistance to other NRTIs.
  • OBJECTIVES: This paper describes the development of ATC, including its in vitro activity, pharmacokinetics and clinical efficacy and safety.
  • METHODS: The current literature on ATC was reviewed.
  • RESULTS/CONCLUSIONS: ATC is a novel deoxycytidine NRTI with good antiviral activity, both in vitro and in treatment-naïve and treatment-experienced HIV-1-infected patients, including those with resistance to other NRTIs.
  • ATC may have a place in the treatment of patients who have failed previous treatment regimens due to the development of NRTI resistance as a replacement for existing drugs.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Deoxycytidine / analogs & derivatives. HIV Infections / drug therapy. Reverse Transcriptase Inhibitors / therapeutic use

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236266.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Reverse Transcriptase Inhibitors; 0W860991D6 / Deoxycytidine; K1YX059ML1 / apricitabine
  • [Number-of-references] 47
  •  go-up   go-down


16. Tang KT, Lee CH: BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc; 2010 Mar;73(3):113-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.
  • Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85-90% of all thyroid cancers.
  • BRAF(V600E) is present in approximately 50% of PTC and also found in aggressive histologic variants and PTC-derived anaplastic thyroid cancer, but is rare in follicular variants, and not found in follicular thyroid cancer.
  • The tumorigenic role of BRAF(V600E) in the development of PTC was documented in thyroid-targeted BRAF(V600E) transgenic mice, and rat thyroid cells overexpressed with BRAF(V600E) suggested that BRAF(V600E) is an initiator of tumorigenesis and is required for tumor progression in PTC.
  • The association is also observed in patients with papillary thyroid microcarcinomas and low-risk PTC.
  • BRAF-targeted therapies have been developed to treat various human cancers including advanced thyroid cancers.
  • Studies of multi-kinase inhibitors and/or combination with other regimens are underway in the treatment of advanced thyroid cancers.
  • In this article, we review the pathogenesis of PTC, and the clinical implications of BRAF(V600E) mutation in the diagnosis, prognosis and potential targeted therapeutic strategies for thyroid cancers.
  • [MeSH-major] Carcinoma, Papillary / etiology. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20230995.001).
  • [ISSN] 1728-7731
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Number-of-references] 156
  •  go-up   go-down


17. O'Neill JP, Power D, Condron C, Bouchier-Hayes D, Walsh M: Anaplastic thyroid cancer, tumorigenesis and therapy. Ir J Med Sci; 2010 Mar;179(1):9-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid cancer, tumorigenesis and therapy.
  • BACKGROUND: Anaplastic thyroid cancer (ATC) is a fatal endocrine malignancy.
  • Recent insights into thyroid tumorigenesis, post-malignant dedifferentiation and mode of metastatic activity offer new therapeutic strategies.
  • METHODS: An extensive literature search of Medline and Pubmed was conducted to include all published reports on ATC.
  • CONCLUSIONS: Significant progress, in the last 5 years, has been made outlining thyroid tumorigenesis and the progression to anaplasia.
  • [MeSH-major] Thyroid Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cadherins. Cyclins. Disease Progression. Humans. Radiotherapy. Receptor, Epidermal Growth Factor. Vascular Endothelial Growth Factor A. beta Catenin

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2003 Jun;42(6):580-7 [12786894.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):275-82 [16477625.001]
  • [Cites] Am J Surg. 2006 May;191(5):581-7 [16647341.001]
  • [Cites] Head Neck. 2003 Aug;25(8):662-70 [12884350.001]
  • [Cites] Head Neck. 2007 Aug;29(8):765-72 [17274052.001]
  • [Cites] J Cell Physiol. 2006 Dec;209(3):686-94 [17001684.001]
  • [Cites] Growth Factors. 2006 Mar;24(1):13-9 [16393691.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1161-70 [17317825.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12 (2):600-7 [16428506.001]
  • [Cites] Cancer Sci. 2007 Sep;98(9):1303-10 [17608770.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):987-96 [11238046.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):928-35 [15562011.001]
  • [Cites] Endocrine. 2007 Apr;31(2):105-13 [17873319.001]
  • [Cites] Ann Surg. 2000 Mar;231(3):329-38 [10714625.001]
  • [Cites] Surgery. 2006 Dec;140(6):899-905; discussion 905-6 [17188136.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10199-207 [16288007.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):453-64 [16474910.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4B):2515-22 [17695547.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3716-25 [15867367.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):370-9 [11788678.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Sep;131(9):585-90 [16021466.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):719-29 [17115102.001]
  • [Cites] Eur J Endocrinol. 2007 Apr;156(4):425-30 [17389456.001]
  • [Cites] Oncogene. 1989 Feb;4(2):159-64 [2648253.001]
  • [Cites] Thyroid. 2004 Nov;14 (11):889-95 [15671766.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2261-8 [15880523.001]
  • [Cites] World J Surg. 2001 May;25(5):617-22 [11369989.001]
  • [Cites] World J Surg. 2007 May;31(5):969-77 [17483987.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1247-53 [11889195.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1330-5 [15739211.001]
  • [Cites] Surg Oncol. 2003 Aug;12(2):69-90 [12946479.001]
  • [Cites] BMC Cancer. 2005 Jul 19;5:80 [16029487.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):671-7 [10934169.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):621-8 [17270245.001]
  • [Cites] Cancer Lett. 1995 Aug 16;95(1-2):135-8 [7656221.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):302-8 [10634403.001]
  • [Cites] Eur J Cancer. 2002 Aug;38(12):1661-70 [12142058.001]
  • [Cites] J Clin Invest. 1993 Jan;91(1):179-84 [8423216.001]
  • [Cites] Thyroid. 1998 Aug;8(8):715-26 [9737368.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1030:69-77 [15659782.001]
  • [Cites] Nucl Med Biol. 2006 Oct;33(7):875-82 [17045167.001]
  • [Cites] Oncogene. 1995 Oct 19;11(8):1569-79 [7478581.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):57-64 [11833496.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 [14602780.001]
  • [Cites] Endocr Pathol. 2007 Spring;18(1):1-7 [17652794.001]
  • [Cites] J Surg Oncol. 2006 Dec 15;94(8):662-9 [17131411.001]
  • [Cites] Mol Cancer Ther. 2005 Apr;4(4):632-40 [15827337.001]
  • [Cites] Head Neck. 1996 Jan-Feb;18(1):36-41 [8774920.001]
  • [Cites] Laryngoscope. 2007 Apr;117(4):674-9 [17429874.001]
  • [Cites] Mol Cancer Ther. 2007 Jun;6(6):1785-92 [17575107.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1811-5 [10213482.001]
  • [Cites] Curr Biol. 2002 Jul 9;12(13):R458-60 [12121637.001]
  • [Cites] Arch Surg. 2007 Aug;142(8):717-27; discussion 727-9 [17709725.001]
  • [Cites] Oncol Rep. 2002 Sep-Oct;9(5):915-28 [12168049.001]
  • (PMID = 19662494.001).
  • [ISSN] 1863-4362
  • [Journal-full-title] Irish journal of medical science
  • [ISO-abbreviation] Ir J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cadherins; 0 / Cyclins; 0 / Vascular Endothelial Growth Factor A; 0 / beta Catenin; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 54
  •  go-up   go-down


18. Zhu W, Hu H, Qiu P, Yan G: Triptolide induces apoptosis in human anaplastic thyroid carcinoma cells by a p53-independent but NF-kappaB-related mechanism. Oncol Rep; 2009 Dec;22(6):1397-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triptolide induces apoptosis in human anaplastic thyroid carcinoma cells by a p53-independent but NF-kappaB-related mechanism.
  • This study investigates the pro-apoptotic function and the functional mechanism of triptolide on anaplastic thyroid carcinoma (ATC) cells.
  • Experiments presented here demonstrated that triptolide had dose-dependent effects on cell viability of human ATC cell line TA-K cells through inducing cell apoptosis.
  • [MeSH-major] Apoptosis. Carcinoma / drug therapy. Diterpenes / pharmacology. Gene Expression Regulation, Neoplastic. NF-kappa B / metabolism. Phenanthrenes / pharmacology. Thyroid Neoplasms / drug therapy. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19885592.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Diterpenes; 0 / Epoxy Compounds; 0 / NF-kappa B; 0 / Phenanthrenes; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 19ALD1S53J / triptolide
  •  go-up   go-down


19. Maegele M: Acute traumatic coagulopathy: Incidence, risk stratification and therapeutic options. World J Emerg Med; 2010;1(1):12-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute traumatic coagulopathy: Incidence, risk stratification and therapeutic options.
  • A synopsis is presented of different retrospective analyses based upon datasets from severe multiply injured patients derived from the TR-DGU database (Trauma Registry of the Deutsche Gesellschaft fur Unfallchirurgie (DGU)/ German Society of Trauma Surgery) with respect to frequency, risk stratification and therapeutic options of acute traumatic coagulopathy (ATC).
  • METHODS: The synopsis of different analyses based upon the datasets from severe multiply injured patients derived from the TR-DGU database and development/validation of a scoring system (TASH-score = Trauma Associated Severe Hemorrhage) that allows an early and reliable estimation for the probability of massive transfusion as a surrogate for life-threatening hemorrhage after severe multiple injuries.
  • RESULTS: The high frequency of ATC upon emergency room admission is associated with significant morbidity and mortality in multiply injured patients.
  • The TASH-score is recognized as an easy-to-calculate and valid scoring system to predict the individual's probability for massive transfusion and thus ongoing life-threatening hemorrhage at a very early stage after severe multiple injuries.
  • CONCLUSION: An early aggressive management of ATC including a more balanced administration of blood products to improve outcome is advocated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25214935.001).
  • [ISSN] 1920-8642
  • [Journal-full-title] World journal of emergency medicine
  • [ISO-abbreviation] World J Emerg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4129771
  • [Keywords] NOTNLM ; Coagulopathy / Epidemiology / Management / Risk stratification / Trauma
  •  go-up   go-down


20. Banito A, Pinto AE, Espadinha C, Marques AR, Leite V: Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours. Clin Endocrinol (Oxf); 2007 Nov;67(5):706-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.
  • OBJECTIVE: Follicular thyroid tumours present several genetic alterations such as aneuploidy, RAS mutations and PAX8/PPARgammarearrangements.
  • The molecular basis of aneuploidy remains undefined in the majority of human cancers.
  • The aim of our study was to investigate the correlation between aneuploidy, RAS mutations and PAX8/PPARgamma gene rearrangement in thyroid follicular tumours.
  • DESIGN: Ploidy status was determined by flow cytometry in 111 thyroid lesions (42 follicular thyroid adenomas, 27 follicular thyroid carcinomas, 19 follicular variants of papillary thyroid carcinoma, 20 poorly differentiated thyroid carcinomas and 3 anaplastic thyroid carcinomas).
  • The aneuploid tumours harbouring RAS mutations were two poorly differentiated carcinomas and one follicular variant of papillary thyroid carcinoma with poorly differentiated areas.
  • Three of five (60%) follicular thyroid adenomas and 1 of 7 (14%) follicular thyroid carcinomas, with the PAX8/PPARgamma fusion gene, were aneuploid.
  • CONCLUSIONS: Our data suggest that aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenoma / genetics. Aneuploidy. Genes, ras. Point Mutation. Thyroid Neoplasms / genetics
  • [MeSH-minor] Carcinoma / genetics. Carcinoma, Papillary, Follicular / genetics. DNA Mutational Analysis. Flow Cytometry. Gene Rearrangement. Humans. Oncogene Proteins, Fusion. PPAR gamma / genetics. Paired Box Transcription Factors / genetics. Statistics as Topic

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17651453.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors
  •  go-up   go-down


21. Patel KN, Shaha AR: Poorly differentiated and anaplastic thyroid cancer. Cancer Control; 2006 Apr;13(2):119-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated and anaplastic thyroid cancer.
  • BACKGROUND: Poorly differentiated thyroid carcinoma (PDTC) and anaplastic (undifferentiated) thyroid carcinoma (ATC) comprise a small subset of thyroid tumors that are associated with a poor prognosis and account for a significant portion of the morbidity and mortality related to thyroid cancer.
  • Since management strategies vary between these two entities, it is important for clinicians to be able to differentiate PDTC from ATC.
  • METHODS: We reviewed the literature on PDTC and ATC and compared clinical and histopathologic features important in defining the disease process.
  • RESULTS: Both PDTC and ATC display aggressive behavior with increased locoregional and distant disease.
  • PDTC may represent an intermediate entity in the progression of well-differentiated thyroid carcinoma to ATC.
  • The use of surgical management may be curative or palliative and differs between PDTC and ATC.
  • CONCLUSIONS: PDTC and ATC are rare diseases that carry a poor prognosis.
  • [MeSH-major] Carcinoma / pathology. Thyroid Neoplasms / pathology


22. Metz-Gercek S, Maieron A, Strauss R, Wieninger P, Apfalter P, Mittermayer H: Ten years of antibiotic consumption in ambulatory care: trends in prescribing practice and antibiotic resistance in Austria. BMC Infect Dis; 2009;9:61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The primary aims of this study were (i) to determine the quantity and pattern of antibiotic use in Austria between 1998 and 2007 and (ii) to analyze antibiotic esistance rates in relation to antibiotic consumption in important clinical situations in order to provide data for empirical therapeutic regimens for key indications.
  • METHODS: Consumption data and resistance data were obtained via the Austrian surveillance networks European Antimicrobial Resistance Surveillance System (EARSS) and European Surveillance on Antimicrobial Consumption (ESAC).
  • The Anatomical Therapeutic Chemical (ATC) classification and the Defined Daily Dose (DDD) measurement units were assigned to the data.
  • The percentage of nonsusceptible or intermediate penicillin-resistant pneumococcal isolates remained stable over this time period at around 5%.
  • [MeSH-major] Ambulatory Care / trends. Anti-Bacterial Agents / therapeutic use. Drug Resistance, Bacterial. Practice Patterns, Physicians' / trends. Prescriptions / statistics & numerical data

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Microbiol Infect. 2000 Feb;6(2):59-63 [11168073.001]
  • [Cites] Clin Microbiol Infect. 2008 Jan;14 Suppl 1:104-10 [18154533.001]
  • [Cites] Lancet. 2003 Dec 13;362(9400):1991-2001 [14683661.001]
  • [Cites] Lancet. 2005 Feb 12-18;365(9459):579-87 [15708101.001]
  • [Cites] J Antimicrob Chemother. 2006 Aug;58(2):401-7 [16735414.001]
  • [Cites] J Antimicrob Chemother. 2006 Aug;58(2):408-12 [16735415.001]
  • [Cites] J Antimicrob Chemother. 2006 Aug;58(2):413-7 [16735416.001]
  • [Cites] J Antimicrob Chemother. 2006 Aug;58(2):423-7 [16735418.001]
  • [Cites] Jpn J Infect Dis. 2006 Oct;59(5):299-05 [17060695.001]
  • [Cites] Urology. 2006 Dec;68(6):1169-74 [17169640.001]
  • [Cites] Clin Infect Dis. 2007 Apr 15;44(8):1091-5 [17366456.001]
  • [Cites] Am J Health Syst Pharm. 2007 Dec 1;64(23 Suppl 14):S3-21; quiz S22-4 [18029939.001]
  • [Cites] Med J Aust. 2008 Feb 18;188(4):209-13 [18279126.001]
  • [Cites] BMC Infect Dis. 2008;8:71 [18501015.001]
  • [Cites] J Infect. 2008 Sep;57(3):179-84 [18707763.001]
  • [Cites] Clin Infect Dis. 2008 Nov 1;47(9):1150-8 [18808361.001]
  • [Cites] Clin Infect Dis. 2001 Apr 15;32(8):1162-71 [11283805.001]
  • (PMID = 19439064.001).
  • [ISSN] 1471-2334
  • [Journal-full-title] BMC infectious diseases
  • [ISO-abbreviation] BMC Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Other-IDs] NLM/ PMC2686702
  •  go-up   go-down


23. Swartz EE, Belmore K, Decoster LC, Armstrong CW: Emergency face-mask removal effectiveness: a comparison of traditional and nontraditional football helmet face-mask attachment systems. J Athl Train; 2010 Nov-Dec;45(6):560-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PARTICIPANTS: Twenty-five certified athletic trainers.
  • INTERVENTION(S): The independent variable was face-mask attachment system on 5 levels:.
  • [MeSH-major] Athletic Injuries / epidemiology. Facial Injuries / epidemiology. Football / injuries. Head Protective Devices. Spinal Cord Injuries / epidemiology. Sports Medicine


24. Kim SK, Kim DL, Han HS, Kim WS, Kim SJ, Moon WJ, Oh SY, Hwang TS: Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol; 2008 Jun;17(2):118-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules.
  • BACKGROUND: Fine-needle aspiration biopsy (FNAB) is the primary means of distinguishing benign from malignant and of guiding therapeutic intervention in thyroid nodules.
  • However, 10% to 30% of cases with indeterminate cytology in FNAB need other diagnostic tools to refine diagnosis.
  • In detail, 63 (84.0%) of 75 papillary thyroid carcinoma (PTC) samples showed positive BRAF mutation, whereas 3 follicular thyroid carcinomas, 1 anaplastic carcinoma, 1 medullary thyroid carcinoma, and 1 metastatic lung carcinoma did not show BRAF mutation.
  • Out of 27 thyroid nodules classified as 'indeterminate' on cytologic examination preoperatively, 21 (77.8%) cases turned out to be malignant: 18 PTCs (including 2 follicular variant types) and 3 follicular thyroid carcinomas.
  • Although it was not statistically significant, pyrosequencing was superior to direct DNA sequencing in detecting the BRAF mutation of thyroid nodules (P=0.25).
  • CONCLUSION: Detecting BRAF mutation by pyrosequencing is more sensitive, faster, and less expensive than direct DNA sequencing and is proposed as an adjunct diagnostic tool in evaluating thyroid nodules of indeterminate cytology.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Mutational Analysis / methods. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics. Thyroid Nodule / genetics


25. Chen SN, Xue YQ, Zhang XG, Wu YF, Pan JL, Wang Y, Cen JN: [Establishment and characterization of a human acute monocytic leukemic cell line, SHI-1, carrying t(6;11)(q27;23) and p53 gene alteration]. Zhonghua Xue Ye Xue Za Zhi; 2005 Feb;26(2):94-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Mononuclear cells isolated from the bone marrow of an acute monocytic leukemia (AML-M(5b)) patient at relapse were inoculated in a liquid culture system.
  • The cell line presented typical morphology and immuno-profile of monocytic lineage with the original t(6;11)(q27;q23) and del(17)(p11) abnormalities.
  • A point mutation of ATC-->ACC at exon 6 of the p53 gene was found by sequencing of the PCR products.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921626.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


26. Motti ML, Califano D, Baldassarre G, Celetti A, Merolla F, Forzati F, Napolitano M, Tavernise B, Fusco A, Viglietto G: Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. Carcinogenesis; 2005 Jun;26(6):1021-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas.
  • In the present study, we have characterized several human thyroid cancer cell lines of different histotypes for their responsiveness to contact inhibition.
  • We found that cells derived from differentiated carcinoma (TPC-1, WRO) arrest in G(1) phase at confluence, whereas cells derived from anaplastic carcinoma (ARO, FRO and FB1) continue to grow after reaching confluence.
  • Furthermore, we provide experimental evidence that the axis, E-cadherin/beta-catenin/p27(Kip1), represents an integral part of the regulatory mechanism that controls proliferation at a high cell density, whose disruption may play a key role in determining the clinical behaviour of thyroid cancer.
  • This conclusion derives from the finding that: (i) the expression of p27(Kip1) is enhanced at high cell density only in cells responsive to contact inhibition (TPC-1, WRO), but not in contact-inhibition resistant cells (ARO, FRO or FB1 cells);.
  • In summary, our data indicate that the altered response to contact inhibition exhibited by thyroid anaplastic cancer cells is due to the failure to upregulate p27(Kip1) in response to cell-cell interactions.
  • [MeSH-major] Cadherins / biosynthesis. Carcinoma / metabolism. Cell Cycle Proteins / physiology. Contact Inhibition / physiology. Thyroid Neoplasms / metabolism. Tumor Suppressor Proteins / physiology
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cell Communication. Cell Count. Cell Line, Tumor. Cell Proliferation. Cyclin A / metabolism. Cyclin-Dependent Kinase Inhibitor p27. Cyclin-Dependent Kinases / metabolism. Cyclins / metabolism. Cytoskeletal Proteins / biosynthesis. Gene Expression Regulation, Neoplastic. Humans. Trans-Activators / biosynthesis. beta Catenin

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15718252.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cadherins; 0 / Cell Cycle Proteins; 0 / Cyclin A; 0 / Cyclins; 0 / Cytoskeletal Proteins; 0 / Trans-Activators; 0 / Tumor Suppressor Proteins; 0 / beta Catenin; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.11.22 / Cyclin-Dependent Kinases
  •  go-up   go-down


27. Zhang W, Shen X, Wang Y, Chen Y, Huang M, Zeng Q, Wei J, Lu Q, Wang G, Deng L, Wang X, Yao K, Yu S, Yang Y: Antibiotic use in five children's hospitals during 2002-2006: the impact of antibiotic guidelines issued by the Chinese Ministry of Health. Pharmacoepidemiol Drug Saf; 2008 Mar;17(3):306-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The Anatomical Therapeutic Chemical Classification/Defined Daily Doses (ATC/DDD) methodology was used.
  • Aggregate data on antibiotic use (ATC code-J01) were expressed in numbers of DDD/100 bed-days for inpatients.
  • CONCLUSIONS: The ATC/DDD methodology proved useful for studying overall antibiotic usage in children's hospitals.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Drug Utilization / statistics & numerical data. Guideline Adherence / statistics & numerical data. Hospitals, Pediatric / statistics & numerical data
  • [MeSH-minor] Adolescent. Cephalosporins / therapeutic use. Child. Child, Preschool. China. Databases, Factual. Female. Humans. Infant. Male. Practice Guidelines as Topic. Practice Patterns, Physicians' / statistics & numerical data. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 John Wiley & Sons, Ltd.
  • (PMID = 18165944.001).
  • [ISSN] 1099-1557
  • [Journal-full-title] Pharmacoepidemiology and drug safety
  • [ISO-abbreviation] Pharmacoepidemiol Drug Saf
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Cephalosporins
  •  go-up   go-down


28. Vanatta LE, Woodruff A, Coleman DE: Comparison of two cryptand separator columns for the determination of trace chloride in semiconductor-grade nitric acid. J Chromatogr A; 2005 Aug 26;1085(1):33-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also, the use of a Continuously Regenerated Anion Trap Column (CR-ATC) was evaluated for its ability to purify electrolytically generated eluent.
  • Results also showed that the CR-ATC was necessary for obtaining acceptable acid blanks.

  • Hazardous Substances Data Bank. NITRIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16106844.001).
  • [ISSN] 0021-9673
  • [Journal-full-title] Journal of chromatography. A
  • [ISO-abbreviation] J Chromatogr A
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anion Exchange Resins; 0 / Bicyclo Compounds, Heterocyclic; 0 / Chlorides; 23978-09-8 / cryptating agent 222; 31364-42-8 / cryptating agent 221; 411VRN1TV4 / Nitric Acid
  •  go-up   go-down


29. Cohen JD, Shapiro M, Grozovski E, Lev S, Fisher H, Singer P: Extubation outcome following a spontaneous breathing trial with automatic tube compensation versus continuous positive airway pressure. Crit Care Med; 2006 Mar;34(3):682-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extubation outcome following a spontaneous breathing trial with automatic tube compensation versus continuous positive airway pressure.
  • OBJECTIVE: We hypothesized that the additional use of automatic tube compensation (ATC) during a spontaneous breathing trial with continuous positive airway pressure (CPAP), by minimizing respiratory work, would result in more patients undergoing successful extubation.
  • INTERVENTIONS: Patients were randomized to undergo a 1-hr spontaneous breathing trial with either ATC with CPAP (ATC group, n=51) or CPAP alone (CPAP group, n=48).
  • ATC was provided by commercially available mechanical ventilators.
  • There was a trend for more patients in the ATC group to tolerate the breathing trial and undergo extubation (96% vs. 85%; p=.08).
  • The rate of reintubation was 14% in the ATC group and 24% in the CPAP group (p=.28).
  • Significantly more patients in the ATC group thus met the criteria for successful extubation (82% vs. 65%; p=0.04).
  • CONCLUSION: This is the largest single-center study to date assessing the use of commercially available ATC and suggests that this might be a useful mode for performing a spontaneous breathing trial preceding extubation in a general intensive care population.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Crit Care Med. 2006 Nov;34(11):2867; author reply 2867 [17053584.001]
  • (PMID = 16505653.001).
  • [ISSN] 0090-3493
  • [Journal-full-title] Critical care medicine
  • [ISO-abbreviation] Crit. Care Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


30. Hermes M, Schormann W, Brulport M, Uhlemann K, Lupatsch F, Horn LC, Schumann A, Allgaier C, Weishaupt M, Engeland K, Müller GA, Mössner J, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Lausch E, Prawitt D, Wilhelm C, Hengstler JG: Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model. Br J Cancer; 2008 May 6;98(9):1525-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trastuzumab (Herceptin) has improved therapy of breast cancer.
  • We used a mouse model that allows anhydrotetracycline (ATc)-controlled downregulation of ERBB2 in tumour tissue.
  • Surprisingly, trastuzumab caused a much weaker effect compared to ATc-induced ERBB2 downregulation, although a decrease in ERBB2 membrane localisation was induced.
  • The suboptimal effect of trastuzumab compared to the maximally possible effect induced by ATc demonstrates a high potential for improved ERBB2 blocking therapies.

  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2639-48 [10561337.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Nov;6(7):603-12 [17100566.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4744-9 [11406546.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):719-26 [11821453.001]
  • [Cites] Science. 2002 Jul 5;297(5578):63-4 [12098689.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4132-41 [12124352.001]
  • [Cites] Mol Cancer Ther. 2002 Jul;1(9):707-17 [12479367.001]
  • [Cites] Nature. 2003 Feb 13;421(6924):756-60 [12610629.001]
  • [Cites] Curr Opin Chem Biol. 2003 Aug;7(4):490-5 [12941424.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7221-31 [14612517.001]
  • [Cites] Mol Cell Biol. 1989 Mar;9(3):1165-72 [2566907.001]
  • [Cites] Cancer Res. 1990 Mar 1;50(5):1550-8 [1689212.001]
  • [Cites] Cell. 1990 Apr 20;61(2):203-12 [2158859.001]
  • [Cites] J Biol Chem. 1991 Aug 5;266(22):14300-5 [1677643.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5547-51 [1319065.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):737-44 [8622019.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):901-11 [8806679.001]
  • [Cites] J Drug Target. 2004;12(7):461-71 [15621671.001]
  • [Cites] Clin Breast Cancer. 2005 Aug;6(3):240-6 [16137435.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] Mol Carcinog. 2006 May;45(5):302-8 [16496387.001]
  • [Cites] Science. 2006 May 26;312(5777):1175-8 [16728632.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2619-21 [16775247.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Jun;6(4):333-63 [16848724.001]
  • [Cites] Int J Clin Oncol. 2006 Jun;11(3):199-208 [16850126.001]
  • [Cites] J Clin Oncol. 2006 Aug 10;24(23):3735-46 [16847284.001]
  • [Cites] Breast Cancer. 2006;13(3):236-48 [16929116.001]
  • [Cites] Mol Pharmacol. 2006 Nov;70(5):1534-41 [16887935.001]
  • [Cites] Nat Med. 2000 Apr;6(4):443-6 [10742152.001]
  • (PMID = 18454161.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Ki-67 Antigen; 0 / RNA, Messenger; 0 / Tetracyclines; 680VDL31MX / 4-epianhydrotetracycline; 9007-43-6 / Cytochromes c; EC 2.7.10.1 / Erbb2 protein, mouse; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.11.1 / 3-Phosphoinositide-Dependent Protein Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; P188ANX8CK / Trastuzumab
  • [Other-IDs] NLM/ PMC2391101
  •  go-up   go-down


31. Yard EE, Schroeder MJ, Fields SK, Collins CL, Comstock RD: The epidemiology of United States high school soccer injuries, 2005-2007. Am J Sports Med; 2008 Oct;36(10):1930-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Soccer-related injury data were collected over the 2005-2006 and 2006-2007 school years from 100 nationally representative United States high schools via Reporting Information Online (RIO, an Internet-based sports-related injury surveillance system).
  • RESULTS: Participating certified athletic trainers reported 1524 soccer injuries during 637 446 athlete exposures (AEs), for an injury rate of 2.39 per 1000 AEs, corresponding to a nationally estimated 807 492 soccer-related injuries during the 2005-2006 and 2006-2007 seasons.
  • [MeSH-major] Athletic Injuries / epidemiology. Soccer / injuries

  • MedlinePlus Health Information. consumer health - Sports Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628486.001).
  • [ISSN] 1552-3365
  • [Journal-full-title] The American journal of sports medicine
  • [ISO-abbreviation] Am J Sports Med
  • [Language] eng
  • [Grant] United States / PHS HHS / / R49/ CEOOO674-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


32. Lee EB, Kim JY, Zhao J, Park MH, Song YW: Haplotype association of IL-8 gene with Behcet's disease. Tissue Antigens; 2007 Feb;69(2):128-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haplotype association of IL-8 gene with Behcet's disease.
  • Interleukin-8 (IL-8), a CXC chemokine that recruits and activates inflammatory cells, plays a critical role in the pathogenesis of Behcet's disease (BD).
  • However, the frequency of haplotype TAT inferred from SNPs, IL-8 -353 A/T, -251 A/T and +678 T/C, was significantly higher in patients with BD than controls (5.9 vs 0.0%, P = 0.0001), as was haplotype ATC (6.7 vs 0.0%, P < 0.0001).

  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17257314.001).
  • [ISSN] 0001-2815
  • [Journal-full-title] Tissue antigens
  • [ISO-abbreviation] Tissue Antigens
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / HLA-B Antigens; 0 / HLA-B51 Antigen; 0 / Interleukin-8; 0 / Receptors, Interleukin-8A; 0 / Receptors, Interleukin-8B
  •  go-up   go-down


33. Stedmon AW, Sharples S, Littlewood R, Cox G, Patel H, Wilson JR: Datalink in air traffic management: Human factors issues in communications. Appl Ergon; 2007 Jul;38(4):473-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using a novel air traffic control (ATC) task, two experiments are reported.

  • MedlinePlus Health Information. consumer health - Ergonomics.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17506976.001).
  • [ISSN] 0003-6870
  • [Journal-full-title] Applied ergonomics
  • [ISO-abbreviation] Appl Ergon
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


34. Granados-García M, Cortés-Flores AO, del Carmen González-Ramírez I, Cano-Valdez AM, Flores-Hernández L, Aguilar-Ponce JL: Follicular neoplasms of the thyroid: importance of clinical and cytological correlation. Cir Cir; 2010 Nov-Dec;78(6):473-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular neoplasms of the thyroid: importance of clinical and cytological correlation.
  • BACKGROUND: Thyroid cancer presents as nodules.
  • Thyroid nodules are frequent, but only 5-30% are malignant.
  • RESULTS: From 1,005 cases of thyroid nodules, 121 were follicular neoplasms according to cytology.
  • Malignant cases were comprised of 12 papillary carcinomas, 4 follicular carcinomas, 3 papillary carcinomas-follicular variant, 1 lymphoma, 1 teratoma, 5 medullary carcinomas, 2 insular carcinomas, 1 anaplastic carcinoma and 1 metastatic breast carcinoma.
  • FNAB is a useful tool for initial evaluation of thyroid nodules, but clinical evaluation can enhance predictive value.
  • [MeSH-major] Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21214982.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


35. Hombach-Klonisch S, Bialek J, Trojanowicz B, Weber E, Holzhausen HJ, Silvertown JD, Summerlee AJ, Dralle H, Hoang-Vu C, Klonisch T: Relaxin enhances the oncogenic potential of human thyroid carcinoma cells. Am J Pathol; 2006 Aug;169(2):617-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relaxin enhances the oncogenic potential of human thyroid carcinoma cells.
  • The role of members of the insulin-like superfamily in human thyroid carcinoma is primarily unknown.
  • Here we demonstrate the presence of RLN2 relaxin and relaxin receptor LGR7 in human papillary, follicular, and undifferentiated anaplastic thyroid carcinoma suggesting a specific involvement of relaxin-LGR7 signaling in thyroid carcinoma.
  • Stable transfectants of the LGR7-positive human follicular thyroid carcinoma cell lines FTC-133 and FTC-238 that secrete bioactive proRLN2 revealed this hormone to act as a multifunctional endocrine factor in thyroid carcinoma cells.
  • Although RLN2 did not act as a mitogen, it acted as an autocrine/paracrine factor and significantly increased anchorage-independent growth and thyroid carcinoma cell motility and invasiveness through elastin matrices.
  • We found the intracellular distribution of procath-L specifically altered in RLN2 transfectants, providing first evidence for selective actions of relaxin on the powerful elastinolytic cath-L production, storage, and secretion in thyroid carcinoma cells.
  • Thus, relaxin enhances the oncogenic potential and acts as novel endocrine modulator of invasiveness in human thyroid carcinoma cells.
  • [MeSH-major] Carcinoma / pathology. Relaxin / metabolism. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Guide to Pharmacology. gene/protein/disease-specific - RXFP1 - data and references .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2000 Apr;36(6):787-95 [10762753.001]
  • [Cites] J Cell Biol. 2005 Jan 31;168(3):489-99 [15668295.001]
  • [Cites] Neuroscience. 2000;100(3):663-75 [11098128.001]
  • [Cites] Wound Repair Regen. 2000 Sep-Oct;8(5):361-70 [11186125.001]
  • [Cites] Thyroid. 2000 Dec;10(12):1061-9 [11201850.001]
  • [Cites] Regul Pept. 2001 Mar 2;97(2-3):139-46 [11164949.001]
  • [Cites] J Exp Med. 2001 Apr 16;193(8):881-92 [11304549.001]
  • [Cites] Cancer Gene Ther. 2001 Jul;8(7):522-8 [11498774.001]
  • [Cites] Mol Hum Reprod. 2001 Sep;7(9):799-809 [11517286.001]
  • [Cites] J Neurosci. 2001 Oct 1;21(19):7526-33 [11567042.001]
  • [Cites] FASEB J. 2001 Oct;15(12):2187-95 [11641245.001]
  • [Cites] Curr Opin Immunol. 2002 Feb;14(1):15-21 [11790528.001]
  • [Cites] Science. 2002 Jan 25;295(5555):671-4 [11809971.001]
  • [Cites] Oncogene. 2002 Mar 28;21(14):2245-52 [11948407.001]
  • [Cites] Mol Hum Reprod. 2002 Sep;8(9):789-96 [12200455.001]
  • [Cites] Trends Endocrinol Metab. 2002 Oct;13(8):343-8 [12217491.001]
  • [Cites] Exp Biol Med (Maywood). 2002 Dec;227(11):1047-53 [12486216.001]
  • [Cites] Mol Cell Neurosci. 2003 Feb;22(2):146-61 [12676526.001]
  • [Cites] Int J Oncol. 2003 May;22(5):993-1001 [12684664.001]
  • [Cites] Endocrinology. 2003 Aug;144(8):3683-91 [12865351.001]
  • [Cites] J Clin Invest. 2003 Aug;112(4):517-26 [12925692.001]
  • [Cites] Biochemistry (Mosc). 2003 Jul;68(7):711-7 [12946252.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):513-9 [14520686.001]
  • [Cites] Mol Endocrinol. 2003 Dec;17(12):2639-46 [12933905.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):324-34 [14715868.001]
  • [Cites] Clin Exp Metastasis. 2004;21(2):91-106 [15168727.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36761-70 [15192101.001]
  • [Cites] Endocrinology. 2004 Oct;145(10):4712-20 [15256493.001]
  • [Cites] Breast Cancer Res Treat. 2004 Sep;87(2):157-66 [15377840.001]
  • [Cites] Acta Pathol Microbiol Immunol Scand C. 1984 Apr;92(2):107-12 [6203330.001]
  • [Cites] Annu Rev Biochem. 1986;55:167-93 [2943218.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 May;87(10):3861-5 [1692625.001]
  • [Cites] Anticancer Res. 1992 Jan-Feb;12(1):235-40 [1567172.001]
  • [Cites] Cancer. 1992 Aug 1;70(3):639-43 [1320450.001]
  • [Cites] Mol Endocrinol. 1992 Sep;6(9):1441-50 [1435788.001]
  • [Cites] Life Sci. 1993;52(12):1055-61 [8445994.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):1991-6 [8364879.001]
  • [Cites] J Biol Chem. 1993 Dec 15;268(35):26668-72 [8253799.001]
  • [Cites] J Mol Endocrinol. 1994 Jun;12(3):351-64 [7916973.001]
  • [Cites] EMBO J. 1995 Aug 1;14(15):3599-608 [7641679.001]
  • [Cites] Surgery. 1995 Dec;118(6):1036-40 [7491520.001]
  • [Cites] Endocrinology. 1996 Jul;137(7):3009-13 [8770925.001]
  • [Cites] J Biol Chem. 1996 Nov 1;271(44):27936-41 [8910395.001]
  • [Cites] Annu Rev Physiol. 1997;59:63-88 [9074757.001]
  • [Cites] Cell Tissue Res. 1997 Jul;289(1):109-17 [9182605.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Oct;82(10):3383-8 [9329373.001]
  • [Cites] Endocrinology. 1997 Nov;138(11):4713-20 [9348198.001]
  • [Cites] J Endocrinol. 1960 Nov;21:241-6 [13736410.001]
  • [Cites] J Endocrinol. 1963 Jun;26:331-8 [13944118.001]
  • [Cites] Endocrinology. 1963 Feb;72:337-40 [14015096.001]
  • [Cites] Nat Med. 2005 Feb;11(2):206-13 [15665831.001]
  • [Cites] Ann N Y Acad Sci. 2005 May;1041:449-61 [15956746.001]
  • [Cites] Ann N Y Acad Sci. 2005 May;1041:462-9 [15956747.001]
  • [Cites] Int J Oncol. 2005 Aug;27(2):307-15 [16010410.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):482-7 [10931446.001]
  • (PMID = 16877360.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / RLN2 protein, human; 0 / RNA, Messenger; 0 / RXFP1 protein, human; 0 / Receptors, G-Protein-Coupled; 0 / Receptors, Peptide; 9002-69-1 / Relaxin; 9007-58-3 / Elastin; EC 3.4.- / Cathepsins
  • [Other-IDs] NLM/ PMC1698779
  •  go-up   go-down


36. Tran Cao HS, Kaushal S, Snyder CS, Ongkeko WM, Hoffman RM, Bouvet M: Real-time imaging of tumor progression in a fluorescent orthotopic mouse model of thyroid cancer. Anticancer Res; 2010 Nov;30(11):4415-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-time imaging of tumor progression in a fluorescent orthotopic mouse model of thyroid cancer.
  • There is a need for a clinically relevant mouse model of thyroid cancer that enables real-time, non-invasive monitoring of tumor growth, progression, and drug response over time.
  • Human thyroid cancer cell lines NPA (papillary) and KAK-1 (anaplastic) were stably transfected to express either red or green fluorescent protein.
  • Cancer cells were injected into the thyroid glands of 8-week-old athymic mice.
  • At necropsy, the primary tumor was resected en bloc with the respiratory system for processing and analysis.
  • Both anaplastic and papillary thyroid cancer cell lines led to robust development of orthotopic fluorescent tumors in nude mice.
  • Injection of 5×10(5) cancer cells was sufficient for tumor development.
  • Time to premorbid condition varied between mice and was associated with a primary tumor growth pattern (early local compression of the esophagus vs. late metastatic disease) rather than tumor size.
  • Thus an orthotopic mouse model of thyroid cancer has been developed that replicates the major clinical features of thyroid cancer and enables real-time, non-invasive monitoring of tumor progression.
  • This model should permit preclinical evaluation of novel thyroid cancer therapeutics.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21115887.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA121938; United States / NCI NIH HHS / CA / CA109949; United States / NCI NIH HHS / CA / R33 CA109949; United States / NCI NIH HHS / CA / CA121938; United States / NCI NIH HHS / CA / CA132971; United States / NCI NIH HHS / CA / R01 CA132971; United States / NCI NIH HHS / CA / R21 CA109949
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / Luminescent Proteins; 0 / red fluorescent protein; 147336-22-9 / Green Fluorescent Proteins
  • [Other-IDs] NLM/ NIHMS694772; NLM/ PMC4453926
  •  go-up   go-down


37. Niepomniszcze H, Suárez H, Pitoia F, Pignatta A, Danilowicz K, Manavela M, Elsner B, Bruno OD: Follicular carcinoma presenting as autonomous functioning thyroid nodule and containing an activating mutation of the TSH receptor (T620I) and a mutation of the Ki-RAS (G12C) genes. Thyroid; 2006 May;16(5):497-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular carcinoma presenting as autonomous functioning thyroid nodule and containing an activating mutation of the TSH receptor (T620I) and a mutation of the Ki-RAS (G12C) genes.
  • Most autonomous functioning thyroid nodules (AFTN) are benign thyroid follicular neoplasms.
  • We report a case of follicular carcinoma presenting as an AFTN causing subclinical hyperthyroidism in a 64-year-old woman who had a 6-cm hot nodule in the left thyroid lobe.
  • Genomic DNA was extracted from paraffin-embedded tissues from the tumor and extratumoral thyroid tissue.
  • Sequence analyses revealed point mutations in two different genes: the normal ACC sequence at codon 620 of the TSHR gene was replaced by ATC, changing the threonine by isoleucine (T620I); and the wild-type GGT at codon 12 of Ki-RAS mutated to TGT, replacing glycine by cysteine (G12C).
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / genetics. Gene Expression Regulation, Neoplastic. Genes, ras / genetics. Mutation. Receptors, Thyrotropin / genetics. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756473.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / Receptors, Thyrotropin; 9007-49-2 / DNA; E0399OZS9N / Cyclic AMP
  •  go-up   go-down


38. de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpção LV, Metze K, Ward LS: Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology; 2005 Oct;47(4):391-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
  • AIMS: To investigate the usefulness of immunohistochemical expression and immunolocalization of a panel of thyroid malignancy markers including HBME-1, cytokeratin (CK) 19 and galectin-3.
  • METHODS AND RESULTS: We evaluated 170 thyroid lesions including 148 neoplastic lesions [84 papillary carcinomas (PC), 38 follicular carcinomas (FC), 18 follicular adenomas, one hyalinizing trabecular tumour, five medullary carcinomas, two anaplastic carcinomas] and 22 non-neoplastic lesions (12 adenomatous nodules and 10 Hashimoto's thyroiditis).
  • Although the most helpful marker in terms of sensitivity and specificity for the follicular variant of PC and for FC diagnosis was HBME-1, when we consider the differentiation between cases of follicular variant of papillary carcinoma (FVPC) and FC or adenoma, in terms of percentage of positive cells, galectin-3 and CK 19 were more relevant.
  • CONCLUSIONS: HBME-1 is the most sensitive marker for thyroid malignancy but the three markers may be useful in specific cases.
  • [MeSH-major] Biomarkers, Tumor / analysis. Galectin 3 / metabolism. Keratins / metabolism. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16178894.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / HBME-1 antigen; 68238-35-7 / Keratins
  •  go-up   go-down


39. Buergy D, Weber T, Maurer GD, Mudduluru G, Medved F, Leupold JH, Brauckhoff M, Post S, Dralle H, Allgayer H: Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Int J Cancer; 2009 Aug 15;125(4):894-901
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
  • The identification of high-risk patients with thyroid cancer and the preoperative differentiation between follicular adenoma and carcinoma remain clinically challenging.
  • Our study was conducted to analyze whether the quantification of matrix metalloproteinases (MMPs) and urokinase-type plasminogen activator receptor (u-PAR) and transcription factor binding to the u-PAR promoter improve prognostic predictability and differential diagnosis of thyroid tumors.
  • Tumor/normal tissue was collected from 69 prospectively followed patients with thyroid carcinomas (papillary, medullary, follicular and anaplastic, PTC, MTC, FTC and ATC) or follicular adenomas.
  • Carcinomas except MTC expressed significantly more u-PAR/MMPs than adenomas/normal tissues, this being associated with advanced pT- or M-stages.
  • MMP-1 and MMP-9 were significantly higher in follicular carcinomas than in adenomas.
  • In carcinomas, high u-PAR-gene expression correlated significantly with high MMP-9, the latter being associated with MMP-7 in normal tissues.
  • Poor survival in differentiated tumors was associated in trend (p = 0.07); poor survival of all patients (p = 0.043) and especially of patients with carcinomas of follicular origin (including ATC), but not medullary carcinomas, were significantly associated with high u-PAR-protein (p = 0.015).
  • Quantification of u-PAR is of prognostic relevance in thyroid carcinomas of non-c-cell origin, and u-PAR in part may be regulated nontranscriptionally in thyroid cancers.
  • This is the first study to suggest MMP-1/-9 as significant differentiation markers between follicular adenoma and follicular carcinoma.
  • [MeSH-major] Adenoma / metabolism. Biomarkers, Tumor / metabolism. Matrix Metalloproteinase 1 / metabolism. Matrix Metalloproteinase 9 / metabolism. Receptors, Urokinase Plasminogen Activator / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adult. Aged. Blotting, Western. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Electrophoretic Mobility Shift Assay. Female. Humans. Immunoenzyme Techniques. Luciferases. Male. Matrix Metalloproteinase 7 / metabolism. Middle Aged. Prognosis. Promoter Regions, Genetic / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480010.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Urokinase Plasminogen Activator; EC 1.13.12.- / Luciferases; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


40. Soto-Pérez-de-Celis E, González-Pezzat I: Anaplastic thyroid carcinoma. Intern Med J; 2010 May;40(5):383
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid carcinoma.
  • [MeSH-major] Carcinoma / radiography. Thyroid Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20575995.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


41. Zitzelsberger H, Thomas G, Unger K: Chromosomal aberrations in thyroid follicular-cell neoplasia: in the search of novel oncogenes and tumour suppressor genes. Mol Cell Endocrinol; 2010 May 28;321(1):57-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal aberrations in thyroid follicular-cell neoplasia: in the search of novel oncogenes and tumour suppressor genes.
  • Thyroid cancer derived from the follicular cell is characterised by specific gene alterations that are closely linked to the various pathological types comprising papillary, follicular and anaplastic thyroid cancer.
  • This situation, coupled with the demonstration of genetic heterogeneity in thyroid cancer, is a strong motivation for the search of novel gene alterations.
  • Chromosomal aberrations are a good starting point to initiate this search and therefore the current knowledge on chromosomal alterations in thyroid follicular-cell neoplasia is reviewed in this article.
  • The identification of novel genetic markers in thyroid cancer will be further improved by integrative approaches combining data from genomic and expression analyses with clinical data.
  • This approach is powerful to identify genetic markers as well as new therapeutic targets in follicular-cell thyroid cancer.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Chromosome Aberrations. Genes, Tumor Suppressor. Oncogenes / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19961897.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Number-of-references] 110
  •  go-up   go-down


42. Närhi U, Vanakoski J, Sihvo S: Switching of H(2)-Receptor Antagonists to Over-the-Counter Status in Finland : Implications for Consumption and Adverse Effects. Clin Drug Investig; 2005;25(4):243-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the consumption of H(2)-receptor antagonists, proton pump inhibitors, sucralfate and antacids (A02BA, A02BC, A02BX02 and A02A, respectively, according to the Anatomical Therapeutic Chemical [ATC] classification).
  • RESULTS: The total consumption of medicines for the treatment of peptic ulcer disease and gastro-oesophageal reflux disease increased more than 2-fold from 1990 to 2003 (from 12.8 daily defined doses [DDD]/1000 inhabitants/day to 29.6 DDD/1000 inhabitants/day).
  • Since 1998, proton pump inhibitors have been the most commonly used drug group for the treatment of peptic ulcer and gastro-oesophageal reflux disease in Finland.
  • In 2003, the consumption of proton pump inhibitors was 75% (22.2 DDD/1000 inhabitants/day) of the total consumption of drugs for the treatment of peptic ulcer and gastro-oesophageal reflux disease.
  • However, the total number of reports concerning these ATC groups in the national ADR database is not very high, and therefore patient-based surveys are needed to verify this finding.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Toxicol. 1991 Oct;69(4):253-8 [1683484.001]
  • [Cites] Scand J Gastroenterol. 1997 Sep;32(9):855-61 [9299660.001]
  • (PMID = 17523774.001).
  • [ISSN] 1173-2563
  • [Journal-full-title] Clinical drug investigation
  • [ISO-abbreviation] Clin Drug Investig
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


43. Knopf H: [Medicine use in children and adolescents. Data collection and first results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 May-Jun;50(5-6):863-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most frequently, the boys and girls used medicines for the treatment of respiratory tract conditions (ATC code R00: 16.8%).
  • This was followed by Alimentary System and Metabolism (ATC code A00: 16.0%) and Dermatological Preparations (ATC code D00: 9.7%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17514472.001).
  • [ISSN] 1436-9990
  • [Journal-full-title] Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
  • [ISO-abbreviation] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


44. Mehdi G, Ansari HA, Siddiqui SA: Cytology of anaplastic giant cell carcinoma of the thyroid with osteoclast-like giant cells--a case report. Diagn Cytopathol; 2007 Feb;35(2):111-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytology of anaplastic giant cell carcinoma of the thyroid with osteoclast-like giant cells--a case report.
  • Anaplastic carcinoma of the thyroid is known for its highly aggressive behaviour and rapid spread.
  • We report a case of anaplastic carcinoma of the thyroid with focal presence of osteoclast-like giant cells occurring in an elderly male patient, diagnosed on aspiration cytology.
  • [MeSH-major] Carcinoma, Giant Cell / pathology. Giant Cells / pathology. Osteoclasts / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17230568.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Schubert I, Köster I, Lehmkuhl G: The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007. Dtsch Arztebl Int; 2010 Sep;107(36):615-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007.
  • BACKGROUND: The goal of this study is to assess changes in the prevalence of attention-deficit/hyperactivity disorder (ADHD) and methylphenidate prescriptions over the period 2000 to 2007 on the basis of data from a German statutory health insurance carrier.
  • Per calender year, 50,000 to 63,000 children and adolescents were retrospectively observed with respect to the documentation of ADHD diagnosis (ICD-10 diagnosis F90) and the prescribing of methylphenidate (ATC: N06BA04).
  • [MeSH-major] Attention Deficit Disorder with Hyperactivity / drug therapy. Attention Deficit Disorder with Hyperactivity / epidemiology. Central Nervous System Stimulants / therapeutic use. Methylphenidate / therapeutic use

  • Genetic Alliance. consumer health - Attention Deficit Disorder.
  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • Hazardous Substances Data Bank. METHYLPHENIDATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Psychiatr Serv. 2008 May;59(5):554-60 [18451016.001]
  • [Cites] Psychiatr Serv. 2009 Feb;60(2):269 [19176429.001]
  • [Cites] Prax Kinderpsychol Kinderpsychiatr. 2009;58(3):170-85 [19435152.001]
  • [Cites] Gesundheitswesen. 2004 Jun;66(6):387-92 [15206042.001]
  • [Cites] Eur J Clin Pharmacol. 2004 Jul;60(5):377-9 [15168100.001]
  • [Cites] Z Kinder Jugendpsychiatr Psychother. 2004 Jul;32(3):157-66 [15357012.001]
  • [Cites] J Child Adolesc Psychopharmacol. 2005 Feb;15(1):62-7 [15741787.001]
  • [Cites] Gesundheitswesen. 2005 Aug-Sep;67(8-9):638-45 [16217718.001]
  • [Cites] Am J Psychiatry. 2006 Apr;163(4):579-85 [16585430.001]
  • [Cites] Clin Drug Investig. 2006;26(3):161-7 [17163247.001]
  • [Cites] Aust N Z J Public Health. 2007 Apr;31(2):120-6 [17461001.001]
  • [Cites] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007 May-Jun;50(5-6):827-35 [17514469.001]
  • [Cites] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007 May-Jun;50(5-6):871-8 [17514473.001]
  • [Cites] Gesundheitswesen. 2007 May;69(5):292-6 [17582546.001]
  • [Cites] Tidsskr Nor Laegeforen. 2007 Sep 20;127(18):2360-2 [17895938.001]
  • [Cites] Rev Epidemiol Sante Publique. 2007 Oct;55(5):357-63 [17889474.001]
  • [Cites] Laeknabladid. 2007 Dec;93(12):825-32 [18057472.001]
  • [Cites] Eur Child Adolesc Psychiatry. 2007 Oct;16(7):430-8 [17468967.001]
  • [Cites] Eur J Clin Pharmacol. 2008 Mar;64(3):311-7 [18026941.001]
  • [Cites] Psychiatr Serv. 2008 May;59(5):507-14 [18451006.001]
  • [CommentIn] Dtsch Arztebl Int. 2010 Dec;107(51-52):919; author reply 919-20 [21249142.001]
  • (PMID = 20948775.001).
  • [ISSN] 1866-0452
  • [Journal-full-title] Deutsches Ärzteblatt international
  • [ISO-abbreviation] Dtsch Arztebl Int
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 207ZZ9QZ49 / Methylphenidate
  • [Other-IDs] NLM/ PMC2947846
  •  go-up   go-down


46. van de Vrie-Hoekstra NW, de Vries TW, van den Berg PB, Brouwer OF, de Jong-van den Berg LT: Antiepileptic drug utilization in children from 1997-2005--a study from the Netherlands. Eur J Clin Pharmacol; 2008 Oct;64(10):1013-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: From the Dutch Interaction Database (IADB.nl) we selected children aged 0-19 years who received at least one prescription for an AED (ATC-code beginning with N03A) between 1997 and 2005.
  • The 50% survival probability (= time period when 50% of children had stopped using AEDs) was around 2 years, with a significantly lower discontinuation of treatment for girls than boys (P = 0.04).
  • [MeSH-major] Anticonvulsants / therapeutic use. Epilepsy / drug therapy
  • [MeSH-minor] Carbamazepine / administration & dosage. Carbamazepine / adverse effects. Carbamazepine / therapeutic use. Child. Databases, Factual. Drug Utilization. Female. Humans. Incidence. Male. Netherlands / epidemiology. Practice Guidelines as Topic. Prevalence. Retrospective Studies. Triazines / administration & dosage. Triazines / adverse effects. Triazines / therapeutic use. Valproic Acid / administration & dosage. Valproic Acid / adverse effects. Valproic Acid / therapeutic use

  • MedlinePlus Health Information. consumer health - Epilepsy.
  • Hazardous Substances Data Bank. CARBAMAZEPINE .
  • Hazardous Substances Data Bank. LAMOTRIGINE .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 2004 Aug;127(Pt 8):1774-84 [15201192.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2004 Mar;13(3):173-9 [15072117.001]
  • [Cites] Br J Clin Pharmacol. 2006 Dec;62(6):660-5 [16796700.001]
  • [Cites] Acta Neurol Scand. 2006 Jun;113(6):405-11 [16674607.001]
  • [Cites] BMJ. 1997 Jan 18;314(7075):180-1 [9022432.001]
  • [Cites] Br J Clin Pharmacol. 2007 Jun;63(6):689-97 [17257162.001]
  • [Cites] Neurology. 2004 Apr 27;62(8):1252-60 [15111659.001]
  • [Cites] Psychiatr Serv. 2006 May;57(5):681-5 [16675763.001]
  • [Cites] N Engl J Med. 1999 Aug 12;341(7):485-9 [10441604.001]
  • [Cites] Acta Neurol Scand. 2001 Jul;104(1):6-11 [11442436.001]
  • [Cites] Eur J Paediatr Neurol. 2006 May;10(3):107-13 [16638642.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2005 Apr;14(4):239-47 [15719354.001]
  • [Cites] Neurology. 2006 Mar 28;66(6 Suppl 3):S37-45 [16567741.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1995 Jan;58(1):44-50 [7823066.001]
  • [Cites] Epilepsia. 2002 Nov;43(11):1402-9 [12423392.001]
  • (PMID = 18618103.001).
  • [ISSN] 1432-1041
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Triazines; 33CM23913M / Carbamazepine; 614OI1Z5WI / Valproic Acid; U3H27498KS / lamotrigine
  •  go-up   go-down


47. Ito Y, Motoo Y, Yoshida H, Iovanna JL, Nakamura Y, Kuma K, Miyauchi A: High level of tumour protein p53-induced nuclear protein 1 (TP53INP1) expression in anaplastic carcinoma of the thyroid. Pathology; 2006 Dec;38(6):545-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High level of tumour protein p53-induced nuclear protein 1 (TP53INP1) expression in anaplastic carcinoma of the thyroid.
  • In this study, we investigated TP531NP1 expression in human thyroid neoplasms.
  • METHODS: We immunohistochemically investigated TP531NP1 in 197 cases of various thyroid neoplasms.
  • All 39 (20 minimally invasive and 19 widely invasive) follicular carcinomas and 20 adenomas were negative for or expressed only low levels of TP531NP1 except for one widely invasive follicular carcinoma.
  • Of 100 papillary carcinomas, only four (4%) expressed high levels of TP531NP1, and the remaining 96 (96%) were classified into the low group.
  • There were no significant relationships between TP531NP1 expression and clinicopathological features of papillary carcinoma.
  • However, 36 of the 38 (94.7%) anaplastic carcinomas expressed high levels of TP531NP1 and the incidence was significantly higher (p<0.0001) than that in other neoplasms.
  • CONCLUSIONS: These findings suggest that TP531NP1 plays a significant role in the progression of anaplastic carcinoma or contributes to anaplastic transformation from papillary or follicular carcinoma, which is in sharp contrast to findings in previous in vitro and in vivo studies.
  • [MeSH-major] Carcinoma / metabolism. Carrier Proteins / metabolism. Heat-Shock Proteins / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Carcinoma, Papillary / pathology. Carcinoma, Papillary, Follicular / metabolism. Carcinoma, Papillary, Follicular / pathology. Gene Expression Regulation, Neoplastic. Humans

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17393983.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Heat-Shock Proteins; 0 / TP53INP1 protein, human
  •  go-up   go-down


48. Wemeau JL, Do Cao C: [Anaplastic thyroid carcinoma]. Ann Endocrinol (Paris); 2008 Jun;69(3):174-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anaplastic thyroid carcinoma].
  • [Transliterated title] Cancers anaplasiques de la thyroïde.
  • Anaplastic thyroid carcinoma may represent the ultimate dedifferentiation step of thyroid tumorigenesis and is one of the poorest cancers in human.
  • It accounts for less than 2% of thyroid cancers and affects older patients in their sixth to eighth decade.
  • Usual clinical presentation is a rapidly growing thyroid mass invading surrounding structures with compressive symptoms.
  • Though cytological results obtained by fine needle aspiration may be suggestive of diagnosis, tissue biopsy for immunohistochemical study can be necessary to exclude lymphoma and to validate aggressive therapies.
  • Patients developing anaplastic thyroid cancer must be referred urgently in cancer centers to plan multimodality therapeutic approach depending on their performance status.
  • Such treatment can provide control of locoregional disease but does not impact on overall survival in patients with distant metastases.
  • The prognosis is dismal with a mean survival of four to nine months after diagnosis.
  • Long survivors are patients with emerging disease presenting a resectable tumor and receiving adjuvant radiotherapy and/or chemotherapy.
  • Therapeutic researches investigate redifferenciation strategies and targeted therapies to inhibit EGF receptors and neoplastic angiogenesis.
  • Primary prevention of this lethal disease may consist of adequate treatment of differentiated thyroid cancers and goiters in elderly.
  • [MeSH-major] Carcinoma / therapy. Thyroid Neoplasms / therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Goiter / complications. Goiter / therapy. Humans. Middle Aged. Thyroid Diseases / complications. Thyroid Diseases / therapy. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18423422.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


49. Lewandowski W, Matsakis D, Panfilo G, Tavella P: Analysis of correlations, and link and equipment noise in the uncertainties of [UTC - UTC(k)]. IEEE Trans Ultrason Ferroelectr Freq Control; 2008 Apr;55(4):750-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of correlations, and link and equipment noise in the uncertainties of [UTC - UTC(k)].
  • We refine our estimate of the uncertainty in [UTC - UTC(k)] by taking into account the contribution of correlations between the links.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18467219.001).
  • [ISSN] 0885-3010
  • [Journal-full-title] IEEE transactions on ultrasonics, ferroelectrics, and frequency control
  • [ISO-abbreviation] IEEE Trans Ultrason Ferroelectr Freq Control
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Wagstaff AS, Arva P: Hearing loss in civilian airline and helicopter pilots compared to air traffic control personnel. Aviat Space Environ Med; 2009 Oct;80(10):857-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: In order to investigate possible hearing loss as a consequence of aviation noise, a comparative analysis of audiometric data from Norwegian Air Traffic Control (ATC) personnel, airline (fixed-wing) pilots, and helicopter pilots was performed.
  • METHODS: Male ATC, airline, and helicopter pilots were selected randomly from the Civil Aviation Authority (CAA) medical files.
  • There were 182 subjects included in the study: 50, 81, and 51 subjects for ATC, helicopter, and airline pilots, respectively.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817237.001).
  • [ISSN] 0095-6562
  • [Journal-full-title] Aviation, space, and environmental medicine
  • [ISO-abbreviation] Aviat Space Environ Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Scott AR, Holbrook EH: Radiology quiz case 1. Anaplastic thyroid carcinoma. Arch Otolaryngol Head Neck Surg; 2008 Apr;134(4):442, 444
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiology quiz case 1. Anaplastic thyroid carcinoma.
  • [MeSH-major] Carcinoma / pathology. Carcinoma / radiography. Thyroid Neoplasms / pathology. Thyroid Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18427014.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Al-Watban FA, Zhang XY: Photodynamic therapy of human undifferentiated thyroid carcinoma-bearing nude mice using topical 5-aminolevulinic acid. Photomed Laser Surg; 2005 Apr;23(2):206-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of human undifferentiated thyroid carcinoma-bearing nude mice using topical 5-aminolevulinic acid.
  • OBJECTIVE: We determined and evaluated the effect of photodynamic therapy (PDT) using topical 5-aminolevulinic acid (ALA) cream in treating human undifferentiated thyroid carcinoma (UTC)-bearing nude mice.
  • BACKGROUND DATA: UTC constitutes almost 10% of thyroid cancers and shows a very poor response to chemotherapy.
  • MATERIALS AND METHODS: UTC tumor was implanted in the right flank of the nude mice after anesthesia.
  • CONCLUSIONS: PDT is effective in delaying the growth of UTC-bearing nude mice using topical ALA cream and laser light with inappropriate parameters.
  • [MeSH-major] Aminolevulinic Acid / pharmacology. Carcinoma / therapy. Photochemotherapy. Photosensitizing Agents / pharmacology. Thyroid Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15910188.001).
  • [ISSN] 1549-5418
  • [Journal-full-title] Photomedicine and laser surgery
  • [ISO-abbreviation] Photomed Laser Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


53. Aguilar G, Jover JL, Soro M, Belda FJ, García-Raimundo M, Maruenda A: Additional work of breathing and breathing patterns in spontaneously breathing patients during pressure support ventilation, automatic tube compensation and amplified spontaneous pattern breathing. Eur J Anaesthesiol; 2005 Apr;22(4):312-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional work of breathing and breathing patterns in spontaneously breathing patients during pressure support ventilation, automatic tube compensation and amplified spontaneous pattern breathing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15892412.001).
  • [ISSN] 0265-0215
  • [Journal-full-title] European journal of anaesthesiology
  • [ISO-abbreviation] Eur J Anaesthesiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Letter
  • [Publication-country] England
  •  go-up   go-down


54. Takarabe M, Okuda S, Itoh M, Tokimatsu T, Goto S, Kanehisa M: Network analysis of adverse drug interactions. Genome Inform; 2008;20:252-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We defined drug target and drug-metabolizing enzymes as interaction factors using information on them in KEGG DRUG, and classified drugs into pharmacological/chemical subgroups.
  • To characterize other interactions without interaction factors, we used the ATC classification system and found an association between interaction mechanisms and pharmacological/chemical subgroups.

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19425139.001).
  • [ISSN] 0919-9454
  • [Journal-full-title] Genome informatics. International Conference on Genome Informatics
  • [ISO-abbreviation] Genome Inform
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Pharmaceutical Preparations; 0 / Receptors, Biogenic Amine; EC 1.14.14.1 / Cytochrome P-450 CYP3A
  •  go-up   go-down


55. Hassan I, Wunderlich A, Slater E, Hoffmann S, Celik I, Zielke A: Antisense p53 decreases production of VEGF in follicular thyroid cancer cells. Endocrine; 2006 Jun;29(3):409-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antisense p53 decreases production of VEGF in follicular thyroid cancer cells.
  • Inactivating mutations of wild-type p53 (WTp53) tumor suppressor gene are common in anaplastic thyroid cancer (ATC) and are associated with poor prognosis.
  • Therefore, the potential of MTp53 knockout by oligodeoxyribonucleotide phosphorothioates (ODNs) to affect VEGF production of undifferentiated thyroid cancer cells with a recessive MTp53 mutation was evaluated.
  • Transfection of undifferentiated thyroid cancer cells with ODN reduced VEGF secretion of FTC-133 cells following transfection by 34% as compared to the negative control (cells transfected with ODN-HIV; p = 0.03).
  • These results suggest that transient MTp53 knockout with ODNs complementary to p53 nucleotide sequences impair secretion of VEGF in the undifferentiated thyroid cancer cell line FTC-133.
  • [MeSH-major] Adenocarcinoma, Follicular / metabolism. Gene Silencing / physiology. Thyroid Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism. Vascular Endothelial Growth Factor A / biosynthesis

  • Genetic Alliance. consumer health - Thyroid cancer, follicular.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1997 Sep;66(1):11-8 [9290687.001]
  • [Cites] Anticancer Res. 2000 Jul-Aug;20(4):2723-8 [10953350.001]
  • [Cites] Thyroid. 2002 Nov;12(11):953-61 [12490072.001]
  • [Cites] Science. 1994 Sep 9;265(5178):1582-4 [7521539.001]
  • [Cites] Cancer Res. 1986 Feb;46(2):467-73 [2416426.001]
  • [Cites] Langenbecks Arch Surg. 1998 Aug;383(3-4):269-75 [9776455.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Oct;83(10):3668-72 [9768682.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Nov;82(11):3741-7 [9360534.001]
  • [Cites] Leuk Lymphoma. 1994 Jan;12(3-4):223-31 [8167553.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):671-7 [10934169.001]
  • [Cites] Surgery. 2001 Dec;130(6):1028-34 [11742333.001]
  • [Cites] Science. 2002 Feb 22;295(5559):1526-8 [11859195.001]
  • [Cites] Science. 1993 Aug 20;261(5124):1004-12 [8351515.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Dec;89(12):6139-45 [15579770.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3498-504 [8855792.001]
  • [Cites] Cancer Res. 1995 Dec 15;55(24):6161-5 [8521408.001]
  • [Cites] Ann Clin Lab Sci. 2003 Spring;33(2):192-9 [12817624.001]
  • [Cites] Horm Res. 1997;47(4-6):145-57 [9167946.001]
  • (PMID = 16943578.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligodeoxyribonucleotides, Antisense; 0 / Tumor Suppressor Protein p53; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


56. McCrory P, Meeuwisse W, Johnston K, Dvorak J, Aubry M, Molloy M, Cantu R: Consensus statement on concussion in sport - the Third International Conference on Concussion in Sport held in Zurich, November 2008. Phys Sportsmed; 2009 Jun;37(2):141-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This document is developed for use by physicians, therapists, certified athletic trainers, health professionals, coaches and other people involved in the care of injured athletes, whether at the recreational, elite, or professional level.
  • [MeSH-major] Athletic Injuries. Brain Concussion

  • MedlinePlus Health Information. consumer health - Concussion.
  • MedlinePlus Health Information. consumer health - Sports Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20048521.001).
  • [ISSN] 0091-3847
  • [Journal-full-title] The Physician and sportsmedicine
  • [ISO-abbreviation] Phys Sportsmed
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 148
  •  go-up   go-down


57. Tomoda C, Moatamed F, Naeim F, Hershman JM, Sugawara M: Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase. Exp Biol Med (Maywood); 2008 Nov;233(11):1433-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase.
  • Indomethacin, a non-steroidal anti-inflammatory drug (NSAID), has been reported to inhibit the growth of medullary thyroid carcinoma (MTC) cells in vitro.
  • Indomethacin inhibited cell growth of all three MTC cell lines but not normal thyroid cells or anaplastic thyroid carcinoma cells.
  • Indomethacin at 25 muM, a putative therapeutic serum indomethacin level, showed potency similar to 100 to 200 nM sunitinib, a receptor tyrosine kinase inhibitor.
  • Since no drug therapy is currently available for MTC, indomethacin may be one of the therapeutic candidates.
  • [MeSH-major] Carcinoma, Medullary / pathology. Cell Cycle / drug effects. Cell Proliferation / drug effects. Cyclooxygenase Inhibitors / pharmacology. Indomethacin / pharmacology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. INDOMETHACIN .
  • Hazardous Substances Data Bank. Calcitonin .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18791128.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carcinoembryonic Antigen; 0 / Cyclooxygenase Inhibitors; 0 / Indoles; 0 / Pyrroles; 0 / Retinoblastoma Protein; 0 / sunitinib; 9007-12-9 / Calcitonin; K7Q1JQR04M / Dinoprostone; XXE1CET956 / Indomethacin
  •  go-up   go-down


58. Kojima M, Suzuki M, Shimizu K, Masawa N: Inflammatory pseudotumor of the thyroid gland showing prominent fibrohistiocytic proliferation. A case report. Endocr Pathol; 2009;20(3):186-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory pseudotumor of the thyroid gland showing prominent fibrohistiocytic proliferation. A case report.
  • Inflammatory pseudotumor of the thyroid gland (IPT) appears to be exceedingly rare.
  • Immunohistochemical study demonstrated that the spindle cells were vimentin+, desmin-, muscle-specific actin+, cytokeratin-, endomysial antibody-, anaplastic lymphoma kinase-, CD34-- CD68+/-, CD99-, cyclin D1-, bcl-2-, and antifollicular dendritic cell antibody-.
  • They include Riedel's thyroiditis, fibrous variant of chronic thyroiditis, papillary carcinoma with exuberant nodular fasciitis-like stroma, paucicellular variant of anaplastic thyroid carcinoma, and solitary fibrous tumor.
  • [MeSH-major] Granuloma, Plasma Cell / pathology. Thyroid Diseases / pathology
  • [MeSH-minor] Aged. Antigens, CD / biosynthesis. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1989 Jun;41(2):139-42 [2724982.001]
  • [Cites] Am J Clin Pathol. 1988 Dec;90(6):715-22 [3057862.001]
  • [Cites] South Med J. 2004 Jun;97(6):598-600 [15255430.001]
  • [Cites] Semin Diagn Pathol. 1998 May;15(2):85-101 [9606801.001]
  • [Cites] Pathol Res Pract. 2007;203(11):813-7 [17822858.001]
  • [Cites] Am J Clin Pathol. 1996 Apr;105(4):388-93 [8604680.001]
  • [Cites] J Endocrinol Invest. 1995 Jun;18(6):460-4 [7594242.001]
  • [Cites] APMIS. 2008 Feb;116(2):167-72 [18321371.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1534-7 [15070909.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):509-20 [17414097.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):761-8 [11395553.001]
  • [Cites] Cancer. 1981 Aug 1;48(3):830-2 [6788356.001]
  • [Cites] Hum Pathol. 1974 Mar;5(2):161-70 [4405879.001]
  • [Cites] Int J Clin Pract. 2001 Jun;55(5):335-6 [11452684.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):569-76 [11406658.001]
  • [Cites] J Surg Oncol. 2006 Oct 1;94(5):385-91 [16967468.001]
  • [Cites] Am J Clin Pathol. 1991 Mar;95(3):309-14 [1996541.001]
  • [Cites] Hum Pathol. 1985 Aug;16(8):848-50 [4018782.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):931-8 [12218210.001]
  • [Cites] Histopathology. 1993 Nov;23(5):501-3 [8314233.001]
  • [Cites] Head Neck. 1989 Mar-Apr;11(2):184-7 [2722494.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1424-8 [11684960.001]
  • [Cites] Am J Surg Pathol. 1995 Aug;19(8):859-72 [7611533.001]
  • [Cites] J Clin Pathol. 1986 Oct;39(10):1105-7 [3782485.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1364-71 [11684952.001]
  • (PMID = 19444653.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor
  •  go-up   go-down


59. Sun F, Sun Y, Yu Z, Zhang D, Zhang J, Song B, Zheng H: Interleukin-10 gene polymorphisms influence susceptibility to cachexia in patients with low-third gastric cancer in a Chinese population. Mol Diagn Ther; 2010 Apr 01;14(2):95-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-10 gene polymorphisms influence susceptibility to cachexia in patients with low-third gastric cancer in a Chinese population.
  • Therefore, we designed this study to investigate whether polymorphisms of the IL10 gene were associated with cachexia in patients with low-third gastric cancer in a Chinese population.
  • METHODS: 190 patients with low-third gastric cancer were included in this study.
  • In a logistic regression analysis adjusted for actual weight and carcinoma stage, the -1082AG genotype was associated with an odds ratio (OR) of 2.45 (95% CI 1.21, 4.96; p = 0.01), and the -819CC genotype was associated with an OR of 3.70 (95% CI 1.20, 11.39; p = 0.02) for cachexia.
  • Furthermore, haplotype analysis of the -1082A/G, -819T/C, and -592A/C SNPs revealed that at least five haplotypes (ATA, ACC, GCC, ACA, and ATC) were present in this Chinese population, and the -1082G/-819C/-592C (GCC) haplotype was associated with a significantly increased risk of cachexia as compared with the ATA haplotype (OR = 2.42; 95% CI 1.17, 5.00; p = 0.02).
  • CONCLUSION: Our results indicate that genetic polymorphisms of IL-10 may influence susceptibility to cachexia in patients with low-third gastric cancer in this Chinese population.
  • [MeSH-major] Asian Continental Ancestry Group / genetics. Cachexia / complications. Cachexia / genetics. Genetic Predisposition to Disease. Interleukin-10 / genetics. Polymorphism, Single Nucleotide / genetics. Stomach Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1999 Aug;30(2):526-30 [10421663.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2006 Sep;9(5):603-6 [16912557.001]
  • [Cites] J Infect Dis. 2009 Feb 1;199(3):451-4 [19099482.001]
  • [Cites] Immunogenetics. 2003 Mar;54(12):896-9 [12671741.001]
  • [Cites] J Dermatol Sci. 2005 Feb;37(2):111-3 [15659329.001]
  • [Cites] Eur J Immunogenet. 1997 Feb;24(1):1-8 [9043871.001]
  • [Cites] Am J Clin Nutr. 2009 Apr;89(4):1164-72 [19244371.001]
  • [Cites] Support Care Cancer. 2008 Mar;16(3):229-34 [18071761.001]
  • [Cites] Eur J Immunogenet. 2002 Jun;29(3):237-40 [12047360.001]
  • [Cites] Nutrition. 2005 Sep;21(9):977-85 [16043325.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):617-23 [12594817.001]
  • [Cites] J Leukoc Biol. 2005 Nov;78(5):1043-51 [16204623.001]
  • [Cites] Ann N Y Acad Sci. 1996 Oct 31;795:410-2 [8958969.001]
  • [Cites] CA Cancer J Clin. 2002 Mar-Apr;52(2):72-91 [11929007.001]
  • [Cites] Am J Clin Nutr. 2006 Jun;83(6):1345-50 [16762946.001]
  • [Cites] Oncologist. 2007;12 Suppl 1:22-34 [17573453.001]
  • [Cites] Transpl Immunol. 1998 Sep;6(3):193-7 [9848226.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2009 May;12(3):227-31 [19339883.001]
  • (PMID = 20359252.001).
  • [ISSN] 1179-2000
  • [Journal-full-title] Molecular diagnosis & therapy
  • [ISO-abbreviation] Mol Diagn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 130068-27-8 / Interleukin-10
  •  go-up   go-down


60. Baitei EY, Zou M, Al-Mohanna F, Collison K, Alzahrani AS, Farid NR, Meyer B, Shi Y: Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma. J Pathol; 2009 Apr;217(5):707-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
  • Activating BRAF mutations have recently been reported in 28-83% of papillary thyroid carcinomas (PTCs).
  • However, it is not known whether aberrant BRAF splicing occurs in thyroid carcinoma.
  • To investigate aberrant BRAF splicing and its association with BRAF mutation in thyroid tumours, we studied aberrant BRAF splicing and BRAF mutation from 68 thyroid tumours.
  • BRAF(V600E) mutation was detected in 20 of 43 PTCs and all three anaplastic thyroid carcinomas (ATCs).
  • Novel BRAF splicing variants were detected in 12 PTCs, three follicular variants of PTC (FVPTCs), and one ATC, as well as in two thyroid carcinoma cell lines, ARO and NPA.
  • These variants did not have the N-terminal auto-inhibitory domain of wild-type B-Raf, resulting in an in-frame truncated protein that contained only the C-terminal kinase domain and caused constitutive activation of B-Raf.
  • These variants were significantly associated with advanced disease stage and BRAF(V600E) mutation (p < 0.001, Fisher exact test).
  • Combination of the BRAF(V600E) mutation and its splicing variants may contribute towards disease progression to poorly differentiated thyroid carcinoma.
  • [MeSH-major] Carcinoma, Papillary / genetics. Proto-Oncogene Proteins B-raf / genetics. RNA Splicing / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adult. Base Sequence. DNA, Neoplasm / genetics. Enzyme Activation / genetics. Humans. MAP Kinase Signaling System / genetics. Middle Aged. Mitogen-Activated Protein Kinases / metabolism. Molecular Sequence Data. Neoplasm Staging. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19156774.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / RNA, Neoplasm; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


61. Takano H, Shibamoto T, Zhang W, Kurata Y: Liver volume, as assessed by four ultrasonic crystals arranged to form a tetrahedron, decreases during anaphylactic shock in anesthetized rats. Shock; 2010 Dec;34(6):586-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The measured relative change of the tetrahedron volume (V[utc]; percentage changes of the initial volume) was closely correlated with the liver weight change (W; percentage changes of the initial liver weight): V(utc) = 0.85W - 4.11 (r² = 0.67).

  • MedlinePlus Health Information. consumer health - Anaphylaxis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20351625.001).
  • [ISSN] 1540-0514
  • [Journal-full-title] Shock (Augusta, Ga.)
  • [ISO-abbreviation] Shock
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


62. Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM: Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer; 2008 Jul 1;113(1):48-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
  • BACKGROUND: Radioactive iodine-refractory (RAIR) 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) positive thyroid carcinomas represent the major cause of deaths from thyroid carcinomas (TC) and are therefore the main focus of novel target therapies.
  • However, to the authors' knowledge, the histology of FDG-PET-positive RAIR metastatic thyroid carcinoma has not been described to date.
  • Poorly differentiated thyroid carcinomas (PDTC) were defined on the basis of high mitotic activity (> or =5 mitoses/10 high-power fields) and/or tumor necrosis.
  • Other types of carcinomas were defined by conventional criteria.
  • The histology of the metastases and primary were analyzed, with disease-specific survival (DSS) as the endpoint.
  • Histologic characterization of the metastasis/recurrence in 70 patients revealed that 47.1% (n = 33 patients) had PDTC, 20% (n = 14 patients) had the tall cell variant (TCV) of papillary thyroid carcinoma, 22.9% (n = 16 patients) had well-differentiated papillary thyroid carcinoma (WDPTC), 8.6% (n = 6 patients) had Hurthle cell carcinoma (HCC), and 1.4% (n = 1 patient) had anaplastic carcinomas.
  • However, well-differentiated RAIR metastatic disease is observable.
  • Poorly differentiated disease is underrecognized in many cases if defined by architectural and nuclear features alone.
  • [MeSH-major] Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Fluorodeoxyglucose F18. Humans. Iodine Radioisotopes. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Positron-Emission Tomography. Radiopharmaceuticals. Survival Analysis


63. Aukerman DF, Aukerman MM, Browning D: Medical coverage of high school athletics in North Carolina. South Med J; 2006 Feb;99(2):132-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary objective of this cross-sectional study was to assess the quality and extent of medical coverage at high school athletic events in North Carolina.
  • METHODS: A questionnaire, mailed to all athletic directors at public and private North Carolina high school members of the North Carolina High School Athletic Association, was used to assess medical coverage.
  • RESULTS: Only 56% of the schools had coverage by either nationally or state certified athletic trainers.
  • Although 71% of schools had physician coverage at some athletic events, less than 10% of physician coverage included monitoring of athletic practices.
  • Only 27% of the schools surveyed felt that their existing medical coverage of athletic events could be considered adequate.
  • [MeSH-major] Athletic Injuries. Emergency Medical Services. Health Services Needs and Demand / statistics & numerical data. School Health Services / statistics & numerical data


64. Fontana GA: Downregulation of cough by exercise and voluntary hyperpnea. Lung; 2010 Jan;188 Suppl 1:S95-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The intensity of the urge-to-cough (UTC), a cognitive component of coughing, was also recorded throughout the trials.
  • The log-log relationship between inhaled fog concentrations and the correspondingly evoked UTC values, an index of the perceptual magnitude of the UTC sensitivity, was also calculated.
  • With exercise and VIH compared with control, mean UTC values at cough threshold were not significantly changed: control, 3.83 +/- 1.11 cm; exercise, 3.12 +/- 0.82 cm; VIH, 4.08 +/- 1.67 cm.
  • Since the slopes of the log fog concentration/log UTC value were approximately halved during exercise and VIH compared with control, the UTC sensitivity to fog was depressed (p < 0.01).


65. Rivera M, Sang C, Gerhard R, Ghossein R, Lin O: Anaplastic thyroid carcinoma: morphologic findings and PAX-8 expression in cytology specimens. Acta Cytol; 2010 Sep-Oct;54(5):668-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid carcinoma: morphologic findings and PAX-8 expression in cytology specimens.
  • OBJECTIVE: To evaluate the morphologic findings most encountered in anaplastic thyroid carcinomas (ATCs) and evaluate for the expression of PAX-8.
  • STUDY DESIGN: The cytology specimens from 21 cases of ATC were evaluated for the following several cytologic criteria: cell morphology, pleomorphism, presence or absence of multinucleated cells, colloid, neutrophilic infiltrate and well-differentiated component.
  • CONCLUSION: ATC is a tumor with diverse morphologic characteristics, and more than 1 cell morphology is usually present.
  • A neutrophilic infiltrate is a common finding and represents a clue to the correct diagnosis.
  • [MeSH-major] Carcinoma / metabolism. Carcinoma / pathology. Paired Box Transcription Factors / metabolism. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Cytodiagnosis. Diagnosis, Differential. Female. Giant Cells / metabolism. Giant Cells / pathology. Humans. Immunoenzyme Techniques. Male

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20968153.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


66. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, Xing M: Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res; 2007 Feb 15;13(4):1161-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
  • PURPOSE: To investigate the overall occurrence and relationship of genetic alterations in the phosphatidylinositol 3-kinase (PI3K)/Akt pathway in thyroid tumors and explore the scope of this pathway as a therapeutic target for thyroid cancer.
  • EXPERIMENTAL DESIGN: We examined collectively the major genetic alterations and their relationship in this pathway, including PIK3CA copy number gain and mutation, Ras mutation, and PTEN mutation, in a large series of primary thyroid tumors.
  • RESULTS: Occurrence of any of these genetic alterations was found in 25 of 81 (31%) benign thyroid adenoma (BTA), 47 of 86 (55%) follicular thyroid cancer (FTC), 21 of 86 (24%) papillary thyroid cancer (PTC), and 29 of 50 (58%) anaplastic thyroid cancer (ATC), with FTC and ATC most frequently harboring these genetic alterations.
  • A mutual exclusivity among these genetic alterations was seen in BTA, FTC, and PTC, suggesting an independent role of each of them through the PI3K/Akt pathway in the tumorigenesis of the differentiated thyroid tumors.
  • However, coexistence of these genetic alterations was increasingly seen with progression from differentiated tumor to undifferentiated ATC.
  • Their coexistence with BRAF mutation was also frequent in PTC and ATC.
  • CONCLUSIONS: The data provide strong genetic implication that aberrant activation of PI3K/Akt pathway plays an extensive role in thyroid tumorigenesis, particularly in FTC and ATC, and promotes progression of BTA to FTC and to ATC as the genetic alterations of this pathway accumulate.
  • Progression of PTC to ATC may be facilitated by coexistence of PI3K/Akt pathway-related genetic alterations and BRAF mutation.
  • The PI3K/Akt pathway may thus be a major therapeutic target in thyroid cancers.
  • [MeSH-major] Oncogene Protein v-akt / genetics. Phosphatidylinositol 3-Kinases / genetics. Thyroid Neoplasms / enzymology. Thyroid Neoplasms / genetics

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317825.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R0-1 CA113507-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / Oncogene Protein v-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


67. Mulder H, Heerdink ER, van Iersel EE, Wilmink FW, Egberts AC: Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study. Ann Pharmacother; 2007 Mar;41(3):408-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In total, 416 drugs metabolized by CYP2D6 were prescribed, with 257 (62%) of these classified as an antidepressant (Anatomical and Therapeutic Chemical [ATC] category N06A) or antipsychotic (ATC N05A).

  • MedlinePlus Health Information. consumer health - Antidepressants.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17341534.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Antipsychotic Agents; EC 1.14.14.1 / Cytochrome P-450 CYP2D6
  •  go-up   go-down


68. Weidner TG, Henning JM: Importance and applicability of approved clinical instructor standards and criteria to certified athletic trainers in different clinical education settings. J Athl Train; 2005 Oct-Dec;40(4):326-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance and applicability of approved clinical instructor standards and criteria to certified athletic trainers in different clinical education settings.
  • CONTEXT: For optimal clinical education of athletic training students, Clinical Instructor Educators and program directors need to proactively select, train, and evaluate their Approved Clinical Instructors (ACIs).
  • OBJECTIVE: To assess the relative importance and applicability of ACI standards to certified athletic trainers employed in different athletic training clinical education settings.
  • CONCLUSIONS: The Weidner and Henning standards are considered to be important and applicable across a variety of athletic training clinical education settings.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16404455.001).
  • [ISSN] 1062-6050
  • [Journal-full-title] Journal of athletic training
  • [ISO-abbreviation] J Athl Train
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1323295
  •  go-up   go-down


69. Haberthür C, Guttmann J: Short-term effects of positive end-expiratory pressure on breathing pattern: an interventional study in adult intensive care patients. Crit Care; 2005 Aug;9(4):R407-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In 30 tracheally intubated, spontaneously breathing patients, we sequentially applied PEEP to the trachea at 0, 5 and 10 cmH2O, and then again at 5 cmH2O for 30 s each, using the automatic tube compensation mode.
  • Post hoc analysis revealed a similar but stronger response in patients with impaired respiratory system compliance.

  • MedlinePlus Health Information. consumer health - Critical Care.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Crit Care Med. 2000 Nov;162(5):1633-40 [11069788.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Sep;160(3):950-60 [10471624.001]
  • [Cites] J Appl Physiol (1985). 2001 Jun;90(6):2330-40 [11356800.001]
  • [Cites] Crit Care Med. 2003 Nov;31(11):2619-26 [14605533.001]
  • [Cites] Technol Health Care. 2003;11(6):413-24 [14757920.001]
  • [Cites] Br Med J. 1974 Jun 22;2(5920):656-9 [4835444.001]
  • [Cites] J Appl Physiol. 1975 May;38(5):869-74 [1126897.001]
  • [Cites] J Appl Physiol. 1975 Mar;38(3):474-80 [168175.001]
  • [Cites] J Pediatr. 1977 Jun;90(6):976-81 [323448.001]
  • [Cites] Respir Physiol. 1981 Sep;45(3):343-55 [6800008.001]
  • [Cites] Am J Physiol. 1986 May;250(5 Pt 2):R902-9 [3706575.001]
  • [Cites] Respir Physiol. 1988 Aug;73(2):145-54 [3420318.001]
  • [Cites] J Appl Physiol (1985). 1990 Mar;68(3):1092-100 [2140347.001]
  • [Cites] J Appl Physiol (1985). 1991 Aug;71(2):474-80 [1938718.001]
  • [Cites] Pediatr Pulmonol. 1991;11(4):345-9 [1758760.001]
  • [Cites] J Appl Physiol (1985). 1992 Mar;72(3):881-7 [1533214.001]
  • [Cites] J Appl Physiol (1985). 1992 Aug;73(2):479-85 [1399969.001]
  • [Cites] Anesthesiology. 1993 Sep;79(3):503-13 [8363076.001]
  • [Cites] Respir Physiol. 1993 Aug;93(2):175-87 [8210757.001]
  • [Cites] Respir Med. 1996 Sep;90(8):463-6 [8869439.001]
  • [Cites] Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):938-44 [8887589.001]
  • [Cites] J Appl Physiol (1985). 1998 Dec;85(6):2033-9 [9843523.001]
  • [Cites] Intensive Care Med. 1999 May;25(5):514-9 [10401948.001]
  • [Cites] Respiration. 2001;68(2):140-4 [11287827.001]
  • (PMID = 16137354.001).
  • [ISSN] 1466-609X
  • [Journal-full-title] Critical care (London, England)
  • [ISO-abbreviation] Crit Care
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  • [Other-IDs] NLM/ PMC1269457
  •  go-up   go-down


70. Raju G, Kameswaran M: Unusual presentations of thyroid malignancies - a case series. Indian J Otolaryngol Head Neck Surg; 2009 Sep;61(3):230-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentations of thyroid malignancies - a case series.
  • Unusual presentations of thyroid neoplasms have been reported from time to time.
  • Four such cases of bizarre presentations of thyroid malignancies seen in the ENT Department of ESIC Hospital, K.K.
  • These cases highlight certain important issues concerning the diagnosis and management.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Otolaryngol. 1979 Oct;8(5):401-10 [501775.001]
  • [Cites] Thorax. 1990 Apr;45(4):293-4 [2192477.001]
  • [Cites] J Laryngol Otol. 1980 Apr;94(4):437-9 [7391670.001]
  • [Cites] J Laryngol Otol. 1999 Feb;113(2):183-5 [10396577.001]
  • [Cites] Med Pregl. 1999 Sep-Oct;52(9-10):395-8 [10624391.001]
  • [Cites] J Laryngol Otol. 2000 Sep;114(9):716-8 [11091840.001]
  • [Cites] Pediatr Hematol Oncol. 2000 Oct-Nov;17(7):591-5 [11033735.001]
  • [Cites] Am J Clin Pathol. 1996 Apr;105(4):388-93 [8604680.001]
  • [Cites] Schweiz Med Wochenschr. 1997 Feb 15;127(7):266-70 [9157532.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Jul;12(1):147-9 [9262098.001]
  • [Cites] Pathol Int. 1999 May;49(5):444-6 [10417688.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1999;256(9):470-2 [10552229.001]
  • [Cites] Minerva Stomatol. 1999 Nov;48(11):535-8 [10768012.001]
  • (PMID = 23120642.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3449984
  • [Keywords] NOTNLM ; Carcinoma, Adenoid cystic / Carcinoma, Anaplastic / Carcinoma, Papillary / Lingual thyroid / Paucicellular variant / Riedel’s thyroiditis / Trachea
  •  go-up   go-down


71. Hogan T, Jing Jie Yu, Williams HJ, Altaha R, Xiaobing Liang, Qi He: Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib. J Oncol Pharm Pract; 2009 Jun;15(2):111-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib.
  • OBJECTIVE: To highlight the molecular findings and clinical response of a patient with rapidly progressing, focally anaplastic, oncocytic thyroid carcinoma (OTC) treated with erlotinib.Case Summary.
  • A 69-year-old woman with recurrent, focally anaplastic OTC was given a therapeutic trial of erlotinib, a small molecule inhibitor of epidermal growth factor receptor (EGFR).
  • CONCLUSION: Erlotinib or other novel protein kinase pathway inhibitors should be evaluated further in patients with aggressive thyroid cancer variants, who may exhibit these and perhaps other tyrosine kinase mutations.
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / pathology. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Thyroid Neoplasms / drug therapy. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276143.001).
  • [ISSN] 1078-1552
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


72. Rapkiewicz A, Roses D, Goldenberg A, Levine P, Bannan M, Simsir A: Encapsulated anaplastic thyroid carcinoma transformed from follicular carcinoma: a case report. Acta Cytol; 2009 May-Jun;53(3):332-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Encapsulated anaplastic thyroid carcinoma transformed from follicular carcinoma: a case report.
  • BACKGROUND: Anaplastic thyroid carcinoma (ATC) is rare but is one of the most aggressive and lethal human malignancies.
  • Cytologically, ATC has a variable morphologic appearance, including squamoid, giant, spindled and pleomorphic cells.
  • The coexistence of ATC and differentiated or poorly differentiated thyroid carcinoma has been described and usually is diagnosed when the disease is locally advanced.
  • CASE: We describe a case of surgically resectable, encapsulated, well-circumscribed ATC occurring in association with a better differentiated follicular carcinoma diagnosed by fine needle aspiration in a patient exposed to external ionizing radiation.
  • CONCLUSION: Encapsulated variants of anaplastic carcinoma can be seen in association with lower grade thyroid carcinoma such as follicular carcinoma.
  • Accurate diagnosis is dependent on adequate sampling.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma / secondary. Cell Transformation, Neoplastic. Chernobyl Nuclear Accident. Neoplasms, Radiation-Induced / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19534279.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


73. Zhang C, Huang Y: Complete mitochondrial genome of Oxya chinensis (Orthoptera, Acridoidea). Acta Biochim Biophys Sin (Shanghai); 2008 Jan;40(1):7-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The initiation codon of the cytochrome oxidase subunit I gene in the mitochondrial genome of O. chinensis appears to be ATC, instead of the tetranucleotides that have been reported in Locusta migratoria (L. migratoria) mitochondrial genome.
  • [MeSH-major] DNA, Mitochondrial / genetics. Genome / genetics. Mitochondria / genetics. Orthoptera / classification. Orthoptera / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18180849.001).
  • [ISSN] 1745-7270
  • [Journal-full-title] Acta biochimica et biophysica Sinica
  • [ISO-abbreviation] Acta Biochim. Biophys. Sin. (Shanghai)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  •  go-up   go-down


74. Datta C, Bhattacharyya S, Ghosh A, Ghosh S: Dedifferentiated papillary carcinoma of thyroid in an adolescent girl--a case report. Indian J Pathol Microbiol; 2005 Oct;48(4):496-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated papillary carcinoma of thyroid in an adolescent girl--a case report.
  • Dedifferentiated papillary carcinoma of thyroid shows combined histopathological features of classical papillary carcinoma and anaplastic carcinoma.
  • [MeSH-major] Carcinoma, Papillary / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366108.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


76. Pohjanoksa-Mäntylä MK, Antila J, Eerikäinen S, Enäkoski M, Hannuksela O, Pietilä K, Airaksinen M: Utilization of a community pharmacy-operated national drug information call center in Finland. Res Social Adm Pharm; 2008 Jun;4(2):144-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority (83%) of these calls were therapeutic or pharmaceutical inquiries, with 26% concerning costs and reimbursements, 14% interactions, 14% dosages, and 11% adverse effects.
  • Nervous system drugs (Anatomical Therapeutic Chemical [ATC] classification N), anti-infectives (J), and musculoskeletal drugs (M) accounted for 20%, 18%, and 13% of the calls, respectively.
  • Nonsteroidal anti-inflammatory drugs (NSAID) (9% of the calls), antidepressants (6%), and penicillin (5%) were the most often inquired about ATC-subgroups.
  • This may especially be the case for certain population groups, and in regard to nervous system drugs, anti-infectives and NSAID.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18555967.001).
  • [ISSN] 1551-7411
  • [Journal-full-title] Research in social & administrative pharmacy : RSAP
  • [ISO-abbreviation] Res Social Adm Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Perrier E, Manen O, Cinquetti G: Essential thrombocytosis and myocardial infarction in an aircrew member: aeromedical concerns. Aviat Space Environ Med; 2006 Jan;77(1):69-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on the case of a 40-yr-old, female French military air traffic controller (ATC) admitted for an ST-elevation myocardial infarction.
  • The diagnosis of ET was then established.
  • No platelet-lowering therapy was prescribed, aspirin was continued, and this ATC was considered unfit for operational duties.
  • [MeSH-major] Military Personnel. Myocardial Infarction / etiology. Thrombocytosis / diagnosis. Work Capacity Evaluation
  • [MeSH-minor] Adult. Aerospace Medicine. Aspirin / therapeutic use. Coronary Angiography. Coronary Thrombosis / radiography. Coronary Thrombosis / therapy. Female. Humans. Platelet Aggregation Inhibitors / therapeutic use. Smoking

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • MedlinePlus Health Information. consumer health - Veterans and Military Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16422458.001).
  • [ISSN] 0095-6562
  • [Journal-full-title] Aviation, space, and environmental medicine
  • [ISO-abbreviation] Aviat Space Environ Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors; R16CO5Y76E / Aspirin
  •  go-up   go-down


78. Koussis H, Maruzzo M, Scola A, Ide EC, Fassina A, Marioni G, Lora O, Corti L, Karachontziti P, Jirillo A: A case of anaplastic thyroid cancer with long-term survival. Anticancer Res; 2010 Apr;30(4):1273-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of anaplastic thyroid cancer with long-term survival.
  • Anaplastic thyroid carcinoma (ATC) (less than 10% of all thyroid cancer) is a high-grade neoplasm, characterized by an aggressive clinical course and refractoriness to currently available local and systemic modalities of treatment.
  • It is considered the most aggressive solid tumour, there is no adequate therapy for this disease and few patients with ATC live more than 1 year following diagnosis.
  • We report herein an unusual case of ATC in a 59-year-old woman.
  • She received many kinds of chemotherapeutical and multimodal treatment; we obtained a long period of localized disease (about two years) and an excellent response to therapy.
  • She is still alive 58 months from diagnosis.
  • [MeSH-major] Carcinoma / therapy. Thyroid Neoplasms / therapy


79. Kondo T, Nakazawa T, Ma D, Niu D, Mochizuki K, Kawasaki T, Nakamura N, Yamane T, Kobayashi M, Katoh R: Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. Lab Invest; 2009 Jul;89(7):791-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas.
  • Thyroid transcription factor-1 (TTF-1), also known as NKX2-1, is a homeodomain containing transcriptional factor identified in thyroid, lung and central nervous system.
  • In the thyroid, TTF-1 is essential for thyroid organogenesis and governs thyroid functions by regulating various thyroid-specific genes.
  • We previously demonstrated that most differentiated thyroid neoplasms, including follicular adenomas/carcinomas and papillary carcinomas, express TTF-1 at both protein and mRNA levels.
  • However, certain subtypes of thyroid cancers have shown low or negative expression of TTF-1.
  • The aim of our study was to investigate the function of epigenetic modification in dysregulation of TTF-1 in thyroid carcinoma cells.
  • We evaluated the expression of TTF-1 in primary thyroid tissues (normal thyroid, papillary carcinoma and undifferentiated carcinoma) and in thyroid carcinoma cell lines using immunohistochemistry and RT-PCR.
  • We also explored whether epigenetic modifiers, including 5-aza-deoxycytidine, could restore TTF-1 expression in thyroid carcinoma cells.
  • In our current study, immunohistochemistry and RT-PCR showed positive expression of TTF-1 in normal thyroids and papillary carcinomas.
  • Meanwhile, most of the undifferentiated carcinomas and the cell lines lost TTF-1 expression.
  • No methylation in the CpG of TTF-1 promoter was detected in normal thyroids or papillary carcinomas.
  • In contrast, DNA methylation was identified in 60% of the undifferentiated carcinomas (6/10) and 50% of the cell lines (4/8).
  • ChIP assay demonstrated that acetylation of H3-lys9 was positively correlated with TTF-1 expression in thyroid carcinoma cells.
  • Finally, DNA demethylating agents could restore TTF-1 gene expression in the thyroid carcinoma cell lines.
  • Our data suggest that epigenetics is involved with inactivation of TTF-1 in thyroid carcinomas, and provide a possible means of using TTF-1 as a target for differentiation-inducing therapy through epigenetic modification.
  • [MeSH-major] DNA Methylation. Gene Silencing. Histones / metabolism. Nuclear Proteins / genetics. Thyroid Neoplasms / genetics. Thyroid Neoplasms / metabolism. Transcription Factors / genetics
  • [MeSH-minor] Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Base Sequence. Carcinoma, Papillary / etiology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / metabolism. Cell Line, Tumor. Chromatin Immunoprecipitation. CpG Islands. DNA Primers / genetics. Epigenesis, Genetic / drug effects. Gene Expression Profiling. Humans. Hydroxamic Acids / pharmacology. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Thyroid Gland / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19506552.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Histones; 0 / Hydroxamic Acids; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 3X2S926L3Z / trichostatin A; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


80. Kopjar N, Zeljezić D, Kasuba V, Rozgaj R: [Antineoplastic drugs as a potential risk factor in occupational settings: mechanisms of action at the cell level, genotoxic effects, and their detection using different biomarkers]. Arh Hig Rada Toksikol; 2010 Mar;61(1):121-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Classification of antineoplastic drugs according to the IARC monographs on the evaluation of carcinogenic risks to humans is accompanied by data on their mutagenicity and the most recent updates in the Anatomical Therapeutic Chemical (ATC) Classification System.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20338875.001).
  • [ISSN] 0004-1254
  • [Journal-full-title] Arhiv za higijenu rada i toksikologiju
  • [ISO-abbreviation] Arh Hig Rada Toksikol
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 212
  •  go-up   go-down


81. Lin D, Ippolito GC, Zong RT, Bryant J, Koslovsky J, Tucker P: Bright/ARID3A contributes to chromatin accessibility of the immunoglobulin heavy chain enhancer. Mol Cancer; 2007 Mar 26;6:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bright positively activates IgH transcriptional initiation by binding to ATC-rich P sites within nuclear matrix attachment regions (MARs) flanking the IgH intronic enhancer (Emu).
  • A system was established in which VH promoter-driven in vitro transcription on chromatin- reconstituted templates was responsive to Emu.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 1991 Oct;11(10):5206-11 [1922040.001]
  • [Cites] Mol Cell Biol. 1991 Oct;11(10):5197-205 [1922039.001]
  • [Cites] Science. 1993 Jul 2;261(5117):82-6 [8316859.001]
  • [Cites] Genes Dev. 1993 Oct;7(10):2016-32 [8406005.001]
  • [Cites] Science. 1994 Aug 26;265(5176):1221-5 [8066460.001]
  • [Cites] J Immunol. 1995 Nov 1;155(9):4270-7 [7594585.001]
  • [Cites] Genes Dev. 1995 Dec 15;9(24):3067-82 [8543152.001]
  • [Cites] J Biol Chem. 1996 Oct 4;271(40):25041-8 [8798787.001]
  • [Cites] EMBO J. 1996 Sep 16;15(18):5014-21 [8890174.001]
  • [Cites] Nature. 1997 Jan 16;385(6613):269-72 [9000077.001]
  • [Cites] Mol Cell Biol. 1997 May;17(5):2658-68 [9111336.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):3527-35 [9199288.001]
  • [Cites] J Immunol. 1998 May 15;160(10):4747-54 [9590220.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3596-603 [9584200.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5121-7 [9710596.001]
  • [Cites] J Biol Chem. 1999 Feb 19;274(8):4858-62 [9988726.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1526-31 [9990057.001]
  • [Cites] J Biol Chem. 1999 May 28;274(22):15633-45 [10336460.001]
  • [Cites] Methods Enzymol. 1999;304:399-414 [10372373.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1998;63:515-24 [10384316.001]
  • [Cites] Immunity. 1999 Jul;11(1):11-20 [10435575.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3741-7 [10446990.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):6632-41 [10490602.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2834-42 [15728493.001]
  • [Cites] Mol Cell Biol. 2005 Mar;25(6):2073-84 [15743806.001]
  • [Cites] Genomics. 2005 Aug;86(2):242-51 [15922553.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14362-7 [16186486.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(6):2187-201 [16507996.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4758-68 [16738337.001]
  • [Cites] Science. 1994 Sep 9;265(5178):1573-7 [8079170.001]
  • [Cites] Genes Dev. 1994 Oct 15;8(20):2453-65 [7958909.001]
  • [Cites] Mol Cell Biol. 1995 Jun;15(6):3217-26 [7760817.001]
  • [Cites] Genes Dev. 1999 Nov 15;13(22):3003-14 [10580007.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 1999;9(3-4):295-310 [10651246.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Cell. 2000 Mar 31;101(1):79-89 [10778858.001]
  • [Cites] EMBO J. 2000 Aug 1;19(15):4123-33 [10921892.001]
  • [Cites] Mol Cell Biol. 2001 Jan;21(1):196-208 [11113195.001]
  • [Cites] Trends Biochem Sci. 2001 Jan;26(1):7-9 [11165500.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1999;64:99-107 [11232342.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1999;64:109-18 [11232275.001]
  • [Cites] Mol Cell Biol. 2001 Apr;21(8):2918-32 [11283269.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):21325-30 [11294836.001]
  • [Cites] EMBO J. 2001 Nov 15;20(22):6394-403 [11707410.001]
  • [Cites] Nat Cell Biol. 2002 Feb;4(2):148-53 [11812999.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2477-87 [12193717.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15030-5 [12415115.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11577-82 [14500909.001]
  • [Cites] J Biol Chem. 2003 Oct 24;278(43):42106-14 [12907668.001]
  • [Cites] Mol Immunol. 2004 Jan;40(10):723-31 [14644098.001]
  • [Cites] J Biomol NMR. 2004 Apr;28(4):357-67 [14872127.001]
  • [Cites] Immunol Rev. 2004 Aug;200:182-96 [15242405.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 May;79(9):2996-3000 [6806821.001]
  • [Cites] Nucleic Acids Res. 1983 Mar 11;11(5):1475-89 [6828386.001]
  • [Cites] Nature. 1986 Oct 9-15;323(6088):548-51 [3093895.001]
  • [Cites] J Biol Chem. 1987 Apr 15;262(11):5394-7 [3031052.001]
  • [Cites] Mol Cell Biol. 1987 Jul;7(7):2558-67 [3039350.001]
  • [Cites] Genes Dev. 1988 Oct;2(10):1227-37 [3264542.001]
  • [Cites] Genes Dev. 1989 Aug;3(8):1255-66 [2792763.001]
  • [Cites] Mol Cell Biol. 1990 Mar;10(3):982-90 [2304473.001]
  • [Cites] Nucleic Acids Res. 1990 May 11;18(9):2643-8 [2111008.001]
  • [Cites] EMBO J. 1993 Jun;12(6):2321-7 [8508765.001]
  • (PMID = 17386101.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / F32 CA110624; United States / NCI NIH HHS / CA / R01 CA031534; United States / NCI NIH HHS / CA / 1F32CA110624-01A1; United States / NCI NIH HHS / CA / CA31534
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ARID3A protein, human; 0 / Chromatin; 0 / DNA-Binding Proteins; 0 / Immunoglobulin Heavy Chains; 0 / Trans-Activators; 0 / Transcription Factors; EC 3.1.- / Deoxyribonucleases
  • [Other-IDs] NLM/ PMC1852116
  •  go-up   go-down


82. Sinorita H, Madiyan M, Pramono RB, Purnama LB, Ikhsan MR, Asdie AH: ACE gene insertion/deletion polymorphism among patients with type 2 diabetes, and its relationship with metabolic syndrome at Sardjito Hospital Yogyakarta, Indonesia. Acta Med Indones; 2010 Jan;42(1):12-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine the ACE genotype of the patients, a genomic DNA fragment on intron 16 of the ACE gene was amplified by polymerase chain reaction (PCR) using a forward primer 5'-CTG GAG ACC ACT CCC ATC CTT TCT-3' and reverse primer 5'-GAT GTG GCC ATC ACA RTC GTC AGA T-3'.


83. Cruciol-Souza JM, Thomson JC: Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci; 2006;9(3):427-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Potential DDI were identified using DrugReax system.
  • Patient's age and gender, number of prescribers; number of drugs and therapeutic drug classes on prescriptions were explored as associated factors to DDI.
  • The rate of potential DDI was significantly associated to in-patients' gender [woman, Odds ratio (OR)=1.23 (P=0.035)], age=55 years old [OR=1.5 (P=0.0008)], number of therapeutic drug class (ATC code, level 1)=4 [OR=5.5 (P=0.0000), cardiology patients [OR=7.87 (P=0.0000)] hospitalized at weekends [OR=1.24 (P=0.039)] and having digoxin prescribed [OR=16.79 (P=0.0000)].
  • A positive correlation was found between DDI, patient's age, number of drugs and therapeutic action ATC codes were significant, controlling for gender (Pearson's r=0.628, P=0.001).

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207423.001).
  • [ISSN] 1482-1826
  • [Journal-full-title] Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Société canadienne des sciences pharmaceutiques
  • [ISO-abbreviation] J Pharm Pharm Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


84. de Oliveira Martins S, Soares MA, Foppe van Mil JW, Cabrita J: Inappropriate drug use by Portuguese elderly outpatients--effect of the Beers criteria update. Pharm World Sci; 2006 Oct;28(5):296-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The drugs were distributed mainly in the following 3 ATC (Anatomical Therapeutic Chemical Classification) classes: C (cardiovascular system), N (nervous system) and A (alimentary tract).
  • According to the ATC Classification, more than one half of the cases of inappropriateness were related with long acting benzodiazepines and with ticlopidine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Geriatr Soc. 2002 Jan;50(1):26-34 [12028243.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2002 Mar;11(2):127-34 [11998537.001]
  • [Cites] Ann Pharmacother. 2002 Mar;36(3):404-9 [11895051.001]
  • [Cites] Arch Intern Med. 1991 Sep;151(9):1825-32 [1888249.001]
  • [Cites] Pharmacotherapy. 2000 Feb;20(2):221-8 [10678301.001]
  • [Cites] Arch Intern Med. 2003 Dec 8-22;163(22):2716-24 [14662625.001]
  • [Cites] Age Ageing. 2000 Jan;29(1):35-9 [10690693.001]
  • [Cites] J Am Geriatr Soc. 2004 Nov;52(11):1934-9 [15507075.001]
  • [Cites] Int J Geriatr Psychiatry. 1999 Apr;14(4):280-4 [10340189.001]
  • [Cites] BMC Geriatr. 2004 Oct 15;4:9 [15488143.001]
  • [Cites] JAMA. 1998 Oct 14;280(14):1249-52 [9786375.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2004 Oct;13(10):669-82 [15386589.001]
  • [Cites] J Am Geriatr Soc. 1994 Dec;42(12):1241-7 [7983285.001]
  • [Cites] Arch Intern Med. 1997 Jul 28;157(14):1531-6 [9236554.001]
  • [Cites] Am J Geriatr Pharmacother. 2003 Dec;1(2):61-74 [15555468.001]
  • [Cites] Ann Pharmacother. 2001 Oct;35(10):1166-72 [11675839.001]
  • [Cites] J Am Geriatr Soc. 1997 Aug;45(8):945-8 [9256846.001]
  • [Cites] Arch Intern Med. 2000 Oct 9;160(18):2825-31 [11025793.001]
  • [Cites] Eur J Intern Med. 2003 Oct;14(6):372-376 [14769496.001]
  • [Cites] J Am Pharm Assoc (Wash). 2000 May-Jun;40(3):417-24 [10853543.001]
  • [Cites] Eur J Clin Pharmacol. 2004 May;60(3):217-20 [15069591.001]
  • [Cites] Ann Pharmacother. 2002 Nov;36(11):1675-81 [12398558.001]
  • [Cites] J Am Pharm Assoc (Wash). 2002 Nov-Dec;42(6):847-57 [12482007.001]
  • [Cites] CMAJ. 1997 Feb 1;156(3):385-91 [9033421.001]
  • [Cites] Am J Geriatr Pharmacother. 2003 Sep;1(1):38-43 [15555464.001]
  • [Cites] J Clin Epidemiol. 1992 Oct;45(10):1045-51 [1474400.001]
  • (PMID = 17111245.001).
  • [ISSN] 0928-1231
  • [Journal-full-title] Pharmacy world & science : PWS
  • [ISO-abbreviation] Pharm World Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


85. Song M, Park JE, Park SG, Lee DH, Choi HK, Park BC, Ryu SE, Kim JH, Cho S: NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26). Biochem Biophys Res Commun; 2009 Apr 17;381(4):491-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since DUSP26 is involved in survival of anaplastic thyroid cancer (ATC) cells, NSC-87877 could be a therapeutic reagent for treating ATC.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19233143.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / NSC-87877; 0 / Quinolines; EC 3.1.3.- / Mitogen-Activated Protein Kinase Phosphatases; EC 3.1.3.48 / DUSP26 protein, human; EC 3.1.3.48 / Dual-Specificity Phosphatases; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 6
  •  go-up   go-down


86. Fernandez NJ, Clark EG, Larson VS: What is your diagnosis? Ventral neck mass in a dog. Vet Clin Pathol; 2008 Dec;37(4):447-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is your diagnosis? Ventral neck mass in a dog.
  • On physical examination, numerous abnormalities were found, including a large ventral neck mass (100 cm(3)) in the area of the thyroid gland.
  • Fine-needle aspirates revealed 2 apparent populations of cells: one suspected to be a well-differentiated thyroid carcinoma, and the other consisting of large pleomorphic to spindloid cells suggestive of sarcoma.
  • A section of the mass was evaluated histologically and a diagnosis of anaplastic thyroid carcinoma was made.
  • Immunohistochemical evaluation with antibodies to thyroglobulin, cytokeratin, and vimentin confirmed distinct populations of malignant epithelial and malignant mesenchymal cells, and the diagnosis was amended to thyroid carcinosarcoma.
  • Thyroid carcinosarcoma is a rare neoplasm in dogs in which the cell type comprising the mesenchymal component can vary.
  • Immunochemistry to demonstrate the 2 cell types may be necessary to differentiate thyroid carcinosarcoma from anaplastic thyroid carcinoma.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055583.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Lee JJ, Foukakis T, Hashemi J, Grimelius L, Heldin NE, Wallin G, Rudduck C, Lui WO, Höög A, Larsson C: Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models. Thyroid; 2007 Apr;17(4):289-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models.
  • In this study we present two novel anaplastic thyroid carcinoma (ATC) lines (HTh 104 and HTh 112) and further characterize six frequently used ATC lines (HTh 7, HTh 74, HTh 83, C 643, KAT-4, and SW 1736).
  • Three of the lines carried a heterozygous BRAF mutation V600E, which is in line with reports of BRAF mutations in primary ATC and papillary thyroid cancer.
  • Several nonrandom breakpoints were identified by spectral karyotyping (SKY) and G-banding in these lines including the novel 1p36 and 17q24-25 as well as 3p21-22 and 15q26 that are also implicated in well-differentiated thyroid cancers.
  • Our results concur with previous studies in both primary tumors and cell lines, indicating that gain of chromosome 20 is important in the pathogenesis of ATC and/or progression of differentiated thyroid cancers to ATC.
  • [MeSH-major] Carcinoma / genetics. Chromosome Aberrations / classification. Chromosomes, Human / genetics. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics


88. Yano Y, Kamma H, Matsumoto H, Fujiwara M, Bando H, Hara H, Yashiro T, Ueno E, Ito K, Uchida K: Growth suppression of thyroid cancer cells by adenylcyclase activator. Oncol Rep; 2007 Aug;18(2):441-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth suppression of thyroid cancer cells by adenylcyclase activator.
  • Thyroid stimulating hormone (TSH) is known to increase intracytoplasmic cyclic adenosine monophosphate (cAMP) and to regulate the growth of normal follicular cells.
  • The aim of this study was to explore the role of the cAMP-mediated signaling pathway stimulated by TSH as a cell growth modulator in human thyroid cancer cells.
  • One papillary thyroid cancer cell line, K1 cells and two anaplastic thyroid cancer cell lines, TTA1 and TTA2 cells were treated with forskolin, which directly activates adenyl cyclase to raise the level of intracellular cAMP.
  • Forskolin suppressed thyroid cancer cell proliferations, especially in K1 cells, in a dose-dependent manner and induced growth arrest at the G0/G1 phase of the cell cycle.
  • In conclusion, we demonstrated that forskolin was involved in G1 arrest and MAPK activation in K1 thyroid cancer cells.
  • Our study suggests that the TSH signal mediated by cAMP acts as a negative regulator in thyroid cancer cells, unlike that in normal follicular cells.
  • [MeSH-minor] Blotting, Western. Cell Cycle / drug effects. Cell Line, Tumor. Dose-Response Relationship, Drug. Enzyme Activation / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Hepatocyte Growth Factor / pharmacology. Humans. Insulin-Like Growth Factor I / pharmacology. MAP Kinase Signaling System / drug effects. Mitogen-Activated Protein Kinase Kinases / metabolism. Phosphorylation / drug effects. Receptors, Thyrotropin / genetics. Receptors, Thyrotropin / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology. Time Factors

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611668.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, Thyrotropin; 1F7A44V6OU / Colforsin; 67256-21-7 / Hepatocyte Growth Factor; 67763-96-6 / Insulin-Like Growth Factor I; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 4.6.1.1 / Adenylyl Cyclases
  •  go-up   go-down


89. Zhang P, Martin PD, Purcarea C, Vaishnav A, Brunzelle JS, Fernando R, Guy-Evans HI, Evans DR, Edwards BF: Dihydroorotase from the hyperthermophile Aquifex aeolicus is activated by stoichiometric association with aspartate transcarbamoylase and forms a one-pot reactor for pyrimidine biosynthesis. Biochemistry; 2009 Feb 03;48(4):766-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In prokaryotes, the first three enzymes in pyrimidine biosynthesis, carbamoyl phosphate synthetase (CPS), aspartate transcarbamoylase (ATC), and dihydroorotase (DHO), are commonly expressed separately and either function independently (Escherichia coli) or associate into multifunctional complexes (Aquifex aeolicus).
  • In mammals the enzymes are expressed as a single polypeptide chain (CAD) in the order CPS-DHO-ATC and associate into a hexamer.
  • This study presents the three-dimensional structure of the noncovalent hexamer of DHO and ATC from the hyperthermophile A. aeolicus at 2.3 A resolution.
  • In the crystal structure, six DHO and six ATC chains form a hollow dodecamer, in which the 12 active sites face an internal reaction chamber that is approximately 60 A in diameter and connected to the cytosol by narrow tunnels.

  • Hazardous Substances Data Bank. OROTIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Genet. 2000 Jan;16(1):9-11 [10637623.001]
  • [Cites] Proteins. 1999 Dec 1;37(4):729-42 [10651286.001]
  • [Cites] Methods Enzymol. 2001;331:248-70 [11265467.001]
  • [Cites] Biochemistry. 2001 Jun 19;40(24):6989-97 [11401542.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10037-41 [11517324.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2001 Oct;57(Pt 10):1451-6 [11567159.001]
  • [Cites] Reproduction. 2002 Jun;123(6):757-68 [12052230.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24490-8 [11959858.001]
  • [Cites] J Synchrotron Radiat. 2003 Jan 1;10(Pt 1):23-5 [12511787.001]
  • [Cites] Proteins. 2003;53 Suppl 6:491-6 [14579338.001]
  • [Cites] Curr Opin Struct Biol. 2003 Dec;13(6):665-73 [14675543.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52924-34 [14534296.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33035-8 [15096496.001]
  • [Cites] Nature. 1968 Jun 22;218(5147):1119-21 [5656633.001]
  • [Cites] Arch Biochem Biophys. 1969 Nov;134(2):352-65 [4311178.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 May;72(5):1712-6 [168571.001]
  • [Cites] J Biol Chem. 1980 Dec 10;255(23):11372-80 [6108322.001]
  • [Cites] J Biol Chem. 1980 Dec 10;255(23):11381-95 [6108323.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(20):6802-6 [2995985.001]
  • [Cites] Methods Enzymol. 1985;113:627-35 [3937019.001]
  • [Cites] J Mol Biol. 1985 Dec 20;186(4):715-24 [3912514.001]
  • [Cites] J Biol Chem. 1986 May 5;261(13):6073-83 [2871022.001]
  • [Cites] Science. 1988 Aug 5;241(4866):669-74 [3041592.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jan;86(1):46-50 [2643106.001]
  • [Cites] Trends Biochem Sci. 1990 Feb;15(2):53-9 [2186515.001]
  • [Cites] Science. 1992 Mar 20;255(5051):1544-50 [1549782.001]
  • [Cites] J Biol Chem. 1995 Jun 30;270(26):15620-7 [7797560.001]
  • [Cites] J Mol Graph. 1996 Feb;14(1):33-8, 27-8 [8744570.001]
  • [Cites] J Bacteriol. 1997 Jun;179(11):3470-81 [9171389.001]
  • [Cites] Eur J Biochem. 1997 Aug 1;247(3):1063-73 [9288932.001]
  • [Cites] Comp Biochem Physiol A Physiol. 1997 Nov;118(3):463-73 [9406429.001]
  • [Cites] Protein Sci. 1998 May;7(5):1083-91 [9605313.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 1998 Jul 1;54(Pt 4):547-57 [9761849.001]
  • [Cites] Adv Microb Physiol. 1998;40:281-351 [9889981.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1240-5 [9990008.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5388-93 [10318893.001]
  • [Cites] Science. 1999 Jul 30;285(5428):751-3 [10427000.001]
  • [Cites] Curr Microbiol. 1999 Oct;39(4):175-9 [10486051.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32 [15572765.001]
  • [Cites] J Biol Chem. 2004 Dec 17;279(51):53136-44 [15381710.001]
  • [Cites] Biochemistry. 2004 Dec 28;43(51):16285-92 [15610022.001]
  • [Cites] J Mol Biol. 2005 May 6;348(3):523-33 [15826651.001]
  • [Cites] J Mol Biol. 2005 May 6;348(3):535-47 [15826652.001]
  • [Cites] Biochemistry. 2005 May 3;44(17):6383-91 [15850372.001]
  • [Cites] Bioinformatics. 2005 Jun 15;21(12):2832-8 [15802286.001]
  • [Cites] J Comput Chem. 2005 Dec;26(16):1668-88 [16200636.001]
  • [Cites] J Comput Chem. 2005 Dec;26(16):1701-18 [16211538.001]
  • [Cites] Proteins. 2005 Dec 1;61(4):704-21 [16231289.001]
  • [Cites] BMC Bioinformatics. 2006;7:316 [16792811.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2007 Jan;63(Pt 1):108-17 [17164533.001]
  • [Cites] Biophys J. 2007 Mar 1;92(5):1792-805 [17172310.001]
  • [Cites] Proteins. 2007 Mar 1;66(4):824-37 [17154422.001]
  • [Cites] Science. 2007 Apr 13;316(5822):254-61 [17431175.001]
  • [Cites] Curr Opin Struct Biol. 2007 Jun;17(3):370-7 [17574831.001]
  • [Cites] J Mol Biol. 2007 Sep 21;372(3):774-97 [17681537.001]
  • [Cites] Science. 2008 Jun 13;320(5882):1428-9 [18556536.001]
  • (PMID = 19128030.001).
  • [ISSN] 1520-4995
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] eng
  • [Databank-accession-numbers] PDB/ 3D6N
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM060371; United States / NHLBI NIH HHS / HL / R01 HL057527; United States / NHLBI NIH HHS / HL / HL47399; United States / NHLBI NIH HHS / HL / HL57527; United States / NIGMS NIH HHS / GM / R01 GM047399; United States / NCI NIH HHS / CA / CA60321; United States / NIGMS NIH HHS / GM / GM60321; United States / NIGMS NIH HHS / GM / GM47399
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Multienzyme Complexes; 0 / Pyrimidines; 155-54-4 / 4,5-dihydroorotic acid; 61H4T033E5 / Orotic Acid; EC 2.1.3.2 / Aspartate Carbamoyltransferase; EC 3.5.2.3 / Dihydroorotase
  • [Other-IDs] NLM/ NIHMS529265; NLM/ PMC3863388
  •  go-up   go-down


90. Federico A, Pallante P, Bianco M, Ferraro A, Esposito F, Monti M, Cozzolino M, Keller S, Fedele M, Leone V, Troncone G, Chiariotti L, Pucci P, Fusco A: Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. Cancer Res; 2009 Sep 1;69(17):7079-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein.
  • Chromobox protein homologue 7 (CBX7) is a chromobox family protein encoding a novel polycomb protein, the expression of which shows a progressive reduction, well related with the malignant grade of the thyroid neoplasias.
  • Indeed, CBX7 protein levels decreased in an increasing percentage of cases going from benign adenomas to papillary, follicular, and anaplastic thyroid carcinomas.
  • Consistent with these data, we found a positive statistical correlation between CBX7 and E-cadherin expression in human thyroid carcinomas.
  • [MeSH-major] Cadherins / metabolism. Carcinoma, Papillary / metabolism. Gene Expression Regulation, Neoplastic. Histone Deacetylases / metabolism. Repressor Proteins / biosynthesis. Repressor Proteins / metabolism

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19706751.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CBX7 protein, human; 0 / Cadherins; 0 / Histone Deacetylase Inhibitors; 0 / Histones; 0 / Repressor Proteins; EC 3.5.1.98 / Hdac2 protein, rat; EC 3.5.1.98 / Histone Deacetylase 2; EC 3.5.1.98 / Histone Deacetylases; EC 6.3.2.19 / Polycomb Repressive Complex 1
  •  go-up   go-down


91. Weijers G, Starke A, Haudum A, Thijssen JM, Rehage J, De Korte CL: Interactive vs. automatic ultrasound image segmentation methods for staging hepatic lipidosis. Ultrason Imaging; 2010 Jul;32(3):143-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interactive vs. automatic ultrasound image segmentation methods for staging hepatic lipidosis.
  • The aim of this study was to test the hypothesis that automatic segmentation of vessels in ultrasound (US) images can produce similar or better results in grading fatty livers than interactive segmentation.
  • A study was performed in postpartum dairy cows (N=151), as an animal model of human fatty liver disease, to test this hypothesis.
  • Ultrasonic tissue characterization (UTC) parameters--Mean echo level, standard deviation (SD) of echo level, signal-to-noise ratio (SNR), residual attenuation coefficient (ResAtt) and axial and lateral speckle size--were derived using a computer-aided US (CAUS) protocol and software package.
  • Automatic-segmentation algorithms were implemented and it was investigated whether better results could be achieved than with the subjective and time-consuming interactive-segmentation procedure.
  • The automatic-segmentation algorithms were based on both fixed and adaptive thresholding techniques in combination with a 'speckle'-shaped moving-window exclusion technique.
  • This enabled us to study the effect of the applied postprocessing steps on single and multiple linear regressions ofthe various UTC parameters with TAG.
  • Improved correlations for all US parameters were found by using automatic-segmentation techniques.
  • Best speckle-size estimates and overall performance (R2 = 0.71, AUC = 0.94) were achieved by using an SNR-based adaptive automatic-segmentation method (used TAG threshold: 50 mg/g liver wet weight).
  • Automatic segmentation is thus feasible and profitable.
  • [MeSH-minor] Algorithms. Animals. Area Under Curve. Biopsy. Cattle. Disease Models, Animal. Female. Linear Models. ROC Curve. Sensitivity and Specificity. Software. Triglycerides / metabolism. Ultrasonography

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20718244.001).
  • [ISSN] 0161-7346
  • [Journal-full-title] Ultrasonic imaging
  • [ISO-abbreviation] Ultrason Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Triglycerides
  •  go-up   go-down


92. Sakji S, Letord C, Pereira S, Dahamna B, Joubert M, Darmoni J: Drug information portal in Europe: information retrieval with multiple health terminologies. Stud Health Technol Inform; 2009;150:497-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DIP has created specific functionalities related to drug and used specific drugs terminologies and classifications: the ATC classification, the CAS numbers, the French codes CIS, and CIP, as well as trade names and the International Nonproprietary Names of the drugs.

  • MedlinePlus Health Information. consumer health - Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19745361.001).
  • [ISSN] 0926-9630
  • [Journal-full-title] Studies in health technology and informatics
  • [ISO-abbreviation] Stud Health Technol Inform
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Pharmaceutical Preparations
  •  go-up   go-down


93. Lin JD, Chao TC: Follicular thyroid carcinoma: From diagnosis to treatment. Endocr J; 2006 Aug;53(4):441-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular thyroid carcinoma: From diagnosis to treatment.
  • Unusual presentations with bone, lung or soft tissue metastases in initial diagnosis of follicular thyroid carcinoma have been reported occasionally.
  • This implies how difficult it is to diagnosis this type of cancer at the pre-operative or intra-operative stage of treatment.
  • Fine needle aspiration cytology has been shown to be an ineffective method for diagnosing vascular or capsule invasion of follicular thyroid cancer.
  • Clinical application of various gene expressions in thyroid follicular tumors by needle aspiration using in situ hybridization requires further investigation.
  • Although radioactive iodide (131I) has been used as the standard treatment for follicular thyroid carcinoma with distant metastases, the effectiveness of 131I treatment for follicular thyroid carcinoma depends on the differentiation of cancer cells.
  • The possibility of 131I for thyroid remnant ablation replacing a secondary operation for follicular thyroid carcinoma has been debated.
  • Recent studies applied more expressions of sodium iodide symporters to attain the effect of 131I treatment and slow the proliferation of thyroid cancer cell which, in turn, slows the progression of follicular carcinoma.
  • Consensus for the surgical procedures for the specific prognostic risks for follicular thyroid carcinoma is needed.
  • Dedifferentiated, anti-angiogenic, or gene therapies for follicular thyroid cancer with distant metastases or anaplastic transformation comprise the principal directions in future research for this cancer.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / therapy. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / therapy
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Carcinoma, Papillary / therapy. Diagnostic Imaging. Humans. Iodine Radioisotopes / therapeutic use. Predictive Value of Tests. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16807500.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Iodine Radioisotopes
  • [Number-of-references] 72
  •  go-up   go-down


94. Zeng Q, Chen G, Vlantis A, Tse G, van Hasselt C: The contributions of oestrogen receptor isoforms to the development of papillary and anaplastic thyroid carcinomas. J Pathol; 2008 Mar;214(4):425-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The contributions of oestrogen receptor isoforms to the development of papillary and anaplastic thyroid carcinomas.
  • Oestrogen (E2) is known to promote the proliferation of thyroid papillary carcinoma cells (KAT5).
  • In the study reported herein, the localization of ER alpha (ERalpha) and beta (ERbeta) in KAT5 and anaplastic carcinoma cells (FRO) was studied by immunofluorescence staining and by immunoblotting the proteins in subcellular fractions.
  • The pattern of the subcellular localization of ERalpha and ERbeta differed between papillary and anaplastic cancer.
  • Upon E2 treatment, the level of ERalpha increased in the nuclei of papillary cancer cells but ERbeta remained unchanged.
  • The level of mitochondrial ERbeta surpassed that of ERalpha in anaplastic cancer cells.
  • The different locations of ERalpha and ERbeta in KAT5 and FRO agreed with the finding that E2 promoted the proliferation of KAT5 but inhibited or did not affect that of FRO cells, and with the proposed functions of these two receptors.
  • E2 inhibited the level of Bax in the mitochondria of papillary cancer, followed by a decrease of cytochrome c and/or apoptosis-inducing factor (AIF) release from the mitochondria into the cytosol.
  • However, in anaplastic cancer, E2 promoted the expression of Bax in the mitochondria and the release of cytochrome c and/or AIF from mitochondria into the cytosol.
  • Our results may explain the differences in epidemiology and responses to anti-tumour therapy between papillary and anaplastic cancer in terms of the subcellular localization of ER isoforms.
  • In conclusion, the findings provide evidence to support the observation that E2 is an important factor in the development of thyroid cancer.
  • The subcellular localization of ERalpha and ERbeta may account for the different pathogenesis of thyroid papillary and anaplastic cancers.
  • [MeSH-major] Carcinoma / metabolism. Carcinoma, Papillary / metabolism. Receptors, Estrogen / metabolism. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. FULVESTRANT .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18085520.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AIFM1 protein, human; 0 / Apoptosis Inducing Factor; 0 / Estrogen Antagonists; 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Estrogens; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / bcl-2-Associated X Protein; 22X328QOC4 / fulvestrant; 4TI98Z838E / Estradiol; 9007-43-6 / Cytochromes c
  •  go-up   go-down


95. Elliott DD, Sherman SI, Busaidy NL, Williams MD, Santarpia L, Clayman GL, El-Naggar AK: Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol; 2008 Jan;39(1):15-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification.
  • Anaplastic thyroid carcinoma is a rare and universally fatal disease.
  • To determine the role of growth factor receptors in the biologic stratification of anaplastic thyroid carcinoma, we studied the expression of epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor beta, and HER-2 receptor in a large cohort of anaplastic thyroid carcinomas by immunohistochemical techniques.
  • The percentage of positive cells, staining intensity and localization of staining in the anaplastic component, and coexisting well-differentiated thyroid carcinoma and adjacent nonneoplastic thyroid were evaluated for these markers.
  • EGFR, platelet-derived growth factor receptor beta, and HER-2 were overexpressed in 58%, 16%, and 16% of anaplastic carcinomas, respectively.
  • In tumors with adjacent normal thyroid parenchyma and/or differentiated carcinoma components, overexpression of all 3 markers was noted exclusively in the anaplastic component.
  • Mutational analysis of exons 18, 19, and 21 of the EGFR gene showed no mutations in all anaplastic carcinomas.
  • We conclude that the expression of these markers (1) may play a role in a subset of thyroid tumorigenesis and anaplastic transformation and (2) can be validated for potential use in the stratification of patients for targeted therapy.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Receptors, Growth Factor / metabolism. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17949783.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Growth Factor; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


96. Ahlstrom U: Work domain analysis for air traffic controller weather displays. J Safety Res; 2005;36(2):159-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Adverse weather conditions have a major impact on National Airspace System (NAS) operations.
  • They create safety hazards for pilots, constrain the usable airspace for air traffic control (ATC), and reduce the overall capacity of the NAS.
  • A system-wide dissemination of weather information to controllers could theoretically improve safety and efficiency.
  • Furthermore, no previous research has empirically evaluated optimal presentation designs for ATC weather displays.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15878775.001).
  • [ISSN] 0022-4375
  • [Journal-full-title] Journal of safety research
  • [ISO-abbreviation] J Safety Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Molander L, Gerstrand M, Rudén C: WikiPharma - a freely available, easily accessible, interactive and comprehensive database for environmental effect data for pharmaceuticals. Regul Toxicol Pharmacol; 2009 Dec;55(3):367-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The database currently contains basic information, i.e. substance name, ATC code(s) and pharmaceutical group(s), for 831 APIs representing 35 different drug classes.
  • [MeSH-minor] Environmental Exposure / adverse effects. Humans. Sweden. Water Pollutants, Chemical / adverse effects

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19720105.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Water Pollutants, Chemical
  •  go-up   go-down


98. Burnett S, Blakemore SJ: Functional connectivity during a social emotion task in adolescents and in adults. Eur J Neurosci; 2009 Mar;29(6):1294-301
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this fMRI study we investigated functional connectivity between components of the mentalising system during a social emotion task, using psychophysiological interaction (PPI) analysis.
  • In both adults and adolescents, an anterior rostral region of medial prefrontal cortex (arMPFC) involved in mentalising showed greater connectivity with the posterior superior temporal sulcus (pSTS) bordering on the temporo-parietal junction (TPJ) and with anterior temporal cortex (ATC) during social than during basic emotion.
  • This result provides novel evidence that components of the mentalising system interact functionally during a social emotion task.
  • The adolescent group showed stronger connectivity between arMPFC and pSTS/TPJ during social relative to basic emotion than did the adult group, suggestive of developmental changes in functional integration within the mentalising system.

  • MedlinePlus Health Information. consumer health - Family Issues.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • SciCrunch. NeuroSynth: Data: Activation Foci .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Neurosci. 1999 Oct;2(10):861-3 [10491603.001]
  • [Cites] J Comp Neurol. 1999 Aug 2;410(3):343-67 [10404405.001]
  • [Cites] Cogn Behav Neurol. 2005 Mar;18(1):68-78 [15761278.001]
  • [Cites] Neuropsychologia. 2005;43(10):1391-9 [15936784.001]
  • [Cites] Nat Rev Neurosci. 2006 Apr;7(4):268-77 [16552413.001]
  • [Cites] Neuroimage. 2006 Apr 15;30(3):1059-68 [16337813.001]
  • [Cites] Behav Brain Res. 2007 Jul 19;181(1):12-22 [17467816.001]
  • [Cites] Neuroimage. 2007 Jul 15;36(4):1065-73 [17513132.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13507-12 [17679691.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):4028-32 [18322013.001]
  • [Cites] Nat Rev Neurosci. 2008 Apr;9(4):267-77 [18354399.001]
  • [Cites] Hum Brain Mapp. 2008 Jun;29(6):696-710 [17598163.001]
  • [Cites] Neuroimage. 2008 Jul 15;41(4):1345-51 [18495496.001]
  • [Cites] J Cogn Neurosci. 2008 Dec;20(12):2125-36 [18457502.001]
  • [Cites] Nat Rev Neurosci. 2008 Dec;9(12):947-57 [19002191.001]
  • [Cites] Hum Brain Mapp. 2009 Jan;30(1):24-37 [17979124.001]
  • [Cites] Cereb Cortex. 2009 Mar;19(3):640-57 [18653667.001]
  • [Cites] Soc Cogn Affect Neurosci. 2007 Jun;2(2):130-9 [17710201.001]
  • [Cites] J Cogn Neurosci. 2009 Sep;21(9):1736-50 [18823226.001]
  • [Cites] Soc Cogn Affect Neurosci. 2006 Sep;1(2):107-21 [18985123.001]
  • [Cites] Soc Cogn Affect Neurosci. 2007 Sep;2(3):217-26 [18985143.001]
  • [Cites] Psychol Rep. 2002 Dec;91(3 Pt 1):743-57 [12530718.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2003 Mar 29;358(1431):459-73 [12689373.001]
  • [Cites] Eur J Neurosci. 2003 Jun;17(11):2475-80 [12814380.001]
  • [Cites] Neuroimage. 2003 Aug;19(4):1835-42 [12948738.001]
  • [Cites] Brain Res Cogn Brain Res. 2003 Dec;18(1):48-57 [14659496.001]
  • [Cites] Neuroreport. 2004 Feb 9;15(2):219-23 [15076740.001]
  • [Cites] Brain Res. 1979 Mar 16;163(2):195-205 [427544.001]
  • [Cites] Neurosci Lett. 1982 Dec 13;33(3):247-52 [7162689.001]
  • [Cites] Arch Gen Psychiatry. 1994 Jun;51(6):477-84 [8192550.001]
  • [Cites] Neuroreport. 1995 Sep 11;6(13):1741-6 [8541472.001]
  • [Cites] Exp Brain Res. 1997 Jul;115(3):430-44 [9262198.001]
  • [Cites] J Comp Neurol. 1997 Oct 20;387(2):167-78 [9336221.001]
  • [Cites] Neuroimage. 1997 Oct;6(3):218-29 [9344826.001]
  • [Cites] Percept Mot Skills. 2004 Oct;99(2):371-91 [15560325.001]
  • (PMID = 19302165.001).
  • [ISSN] 1460-9568
  • [Journal-full-title] The European journal of neuroscience
  • [ISO-abbreviation] Eur. J. Neurosci.
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] S88TT14065 / Oxygen
  • [Other-IDs] NLM/ PMC2695858
  •  go-up   go-down


99. Motti CA, Bourguet-Kondracki ML, Longeon A, Doyle JR, Llewellyn LE, Tapiolas DM, Yin P: Comparison of the biological properties of several marine sponge-derived sesquiterpenoid quinones. Molecules; 2007;12(7):1376-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SAR analyses indicate that a hydroxyquinone functionality and a short, hydroxide/alkoxide side-chain atC-20 is preferred for inhibition of PPDK activity, and that a larger amine side-chain at C-20 is tolerated for PLA2 inhibitory activity.
  • [MeSH-minor] Animals. Anti-Inflammatory Agents / pharmacology. Digitaria / drug effects. Dose-Response Relationship, Drug. Herbicides / pharmacology. Humans. Models, Chemical

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909493.001).
  • [ISSN] 1420-3049
  • [Journal-full-title] Molecules (Basel, Switzerland)
  • [ISO-abbreviation] Molecules
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Herbicides; 0 / Quinones; 0 / Sesquiterpenes
  •  go-up   go-down


100. Saltman B, Singh B, Hedvat CV, Wreesmann VB, Ghossein R: Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression. Surgery; 2006 Dec;140(6):899-905; discussion 905-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression.
  • BACKGROUND: Genetic screening studies suggest that genetic changes underlie progression from well differentiated to anaplastic thyroid cancers.
  • The aim of this study is to determine to what extent cell cycle/apoptosis regulators contribute to cancer progression.
  • METHODS: Tissue microarrarys (TMAs) were constructed from well-differentiated papillary thyroid carcinoma (WDPTC; n = 41), poorly differentiated thyroid carcinoma (PDTC; n = 43), and anaplastic thyroid carcinoma (ATC; n = 22).
  • RESULTS: p53 (0%, 12%, 32%) and Ki-67 (5%, 49%, 82%) were expressed with increasing frequency, and bcl-2 (68%, 42%, 0%) and p21 (40%, 7%, 0%) with decreasing frequency in WDPTC to PDTC and ATC, respectively (P < .001).
  • p27 and cyclin D1 were expressed in <15% of cases, with a trend toward decreasing expression from WDPTC to PDTC to ATC.
  • CONCLUSIONS: These data confirm the presence of increasing genetic complexity with progressive dedifferentiation in thyroid cancer, with aberrant tumor suppressor activity and increased proliferative activity being most prevalent in ATC.
  • The data also confirm the intermediate position of PDTC in the classification scheme of thyroid carcinomas.
  • [MeSH-major] Apoptosis / genetics. Carcinoma / genetics. Carcinoma, Papillary / genetics. Cell Cycle / genetics. Gene Expression Regulation, Neoplastic. Genes, Neoplasm / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cyclin D1 / genetics. Cyclin D1 / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Disease Progression. Humans. Ki-67 Antigen / genetics. Ki-67 Antigen / metabolism. Microarray Analysis. Predictive Value of Tests. Prognosis. Proliferating Cell Nuclear Antigen / genetics. Proliferating Cell Nuclear Antigen / metabolism. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-mdm2 / genetics. Proto-Oncogene Proteins c-mdm2 / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17188136.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / p27 antigen; 136601-57-5 / Cyclin D1; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down






Advertisement